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PD-L1 EXPRESSION BY TUMOR MACROPHAGES: REGULATION AND SIGNALING 
 
Immune checkpoint molecules maintain self-tolerance and prevent uncontrolled 
inflammation. However, expression of these molecules is often dysregulated in the tumor 
microenvironment (TME), resulting in overexpression of inhibitory checkpoint molecules such 
as programmed cell death ligand 1 (PD-L1). This overexpression suppresses T cell activation and 
effector functions, which interferes with T cell control of tumors. PD-1 and its ligand PD-L1 are 
inhibitory checkpoint molecules that suppress tumor immunity, and PD-L1 also binds CD80 to 
inhibit T cell responses. The field of tumor immunotherapy has established that interrupting the 
PD-1/PD-L1 signaling pathway with therapeutic antibodies can potently activate T cell responses 
to tumors. For example, PD-L1 antibody treatment increases T cell infiltration and IFN-γ 
production, and decreases tumor growth in mouse models. Blockade of either molecule with 
specific antibodies has now been shown to induce dramatic anti-tumor responses in patients with 
many tumor types. Importantly, relatively few adverse effects were observed in these trials. 
The excitement generated by these developments in the treatment of human cancers has 
been dampened by the realization that only a small subset of patients respond to immunotherapy. 
This has prompted numerous studies attempting to identify biomarkers that can predict response 
to treatment and has also illuminated the need for animal models that more accurately translate 
human biology and disease progression. Countless therapies developed in rodents have failed to 
successfully treat human disease, but pet dogs with spontaneously-occurring disease are 
emerging as a promising model for many reasons. These include strong similarities in anatomy 
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and physiology between dogs and humans, as well as vast differences in genetics, living 
environment, and diet between dogs that parallel variations found between human patients. 
Furthermore, advances in the care of animals has allowed for longer lifespans for pet dogs, 
which has led to an increase in the incidence of many age-related diseases such as cancer. 
Therefore, the field of comparative oncology utilizes the knowledge gained by treating 
veterinary patients with spontaneously-occurring disease to improve our understanding of human 
disease while also translating therapies used for human care to veterinary patients.  
Very little is known concerning the expression and regulation of canine immune 
checkpoint molecules in either normal tissues or by tumors. Therefore, in the studies described in 
Chapter 2, we measured the expression of PD-L1 by a panel of canine tumor cell lines and by 
primary canine macrophages and further assessed the effects of immune stimuli on PD-L1 
expression by these cells. These studies showed PD-L1 to be constitutively expressed by all 14 
canine tumor cell lines evaluated, and PD-L1 expression was upregulated upon stimulation by 
IFN-γ and a TLR3 ligand. In contrast, canine macrophages did not express PD-L1 under basal 
conditions but expression was induced upon treatment with IFN-γ. These results are consistent 
with those reported in humans and in mice, where PD-L1 is primarily regulated by IFN-γ 
produced by activated T cells. In tumors, this is a mechanism of tumor-mediated T cell 
suppression that is an important target of immunotherapy, and this study suggests that PD-1 and 
PD-L1 blockade may be beneficial for the treatment of canine tumors.    
Lymphoma is one of most commonly diagnosed cancers in dogs, but to-date there has 
been little progress in improving prognosis. Protocols for the treatment of canine lymphoma 
were adapted from those used to treat human patients because chemotherapeutic agents are 
similarly effective between the two patient groups, and at the same time, drugs that are 
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ineffective in humans are also ineffective for dogs. PD-1-targeted immunotherapy has been 
found to be highly effective in the treatment of human lymphoma, and thus canine lymphoma 
may be a disease that benefits from this therapy. Therefore, we characterized the PD-1 and PD-
L1 expression profile in canine lymphoma and the effects of chemotherapy resistance on these 
expression levels, which is detailed in Chapter 3. We first analyzed PD-1 and PD-L1 expression 
using fine needle aspirates of lymph nodes from healthy dogs and from dogs with untreated B 
cell lymphoma (BCL) and T cell lymphoma (TCL). We found increased expression of PD-L1 by 
BCL compared to healthy B cells, but low to negative expression of PD-1 and PD-L1 by both 
healthy and malignant T cells. Next, we generated chemotherapy-resistant BCL and TCL cell 
lines and compared their expression of PD-1 and PD-L1 to untreated cells. We found that 
chemotherapy-resistant BCL cells slightly upregulated PD-1 and PD-L1 while TCL cells more 
significantly upregulated both molecules. We were unable to find a significant difference in the 
expression of PD-1 or PD-L1 between pre- and post-relapse samples from patients with BCL, 
but our in vitro data suggest that this phenomenon would be more apparent in the case of TCL. 
Previous reports show that PD-1 antibodies activate canine T cells in vitro, the first 
administration of a canine PD-L1 antibody showed evidence of clinical activity. These studies 
indicate that PD-1/PD-L1-targeted immunotherapy in canine lymphoma should include a pre-
treatment evaluation of PD-L1 expression levels for use as inclusion or exclusion criteria. 
PD-L1 expression by tumor cells has been the primary focus of numerous studies, but it 
has recently been shown that expression of PD-L1 by myeloid cells in the tumor is a stronger 
marker for both prognosis and for response to immunotherapy. Thus, we investigated the 
regulation of PD-L1 expression by murine monocytes and tumor macrophages in Chapter 4. We 
found that PD-L1 expression by immature bone marrow increased as the monocytes entered 
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circulation and further increased as they matured into macrophages in the tissues. Interestingly, 
tumor macrophages expressed the highest level of PD-L1 expression, implying regulation by the 
tumor microenvironment. We therefore used a combination of in vitro and in vivo methods to 
identify molecules secreted by murine tumor cells that mediate this increased expression of PD-
L1 by tumor macrophages. We found that secretion of versican, an extracellular matrix protein, 
by tumor cells causes monocytes to produce TNF-α, which stimulates the monocytes themselves 
to upregulate PD-L1 expression. Upregulated expression of PD-L1 is one of the mechanisms by 
which tumor macrophages suppress immune responses in the tumor environment and, as a result, 
causes macrophages to be a crucial target for PD-L1-targed immunotherapy. 
Evidence suggests that direct signaling by PD-L1 regulates cellular functions, and that 
treatment with PD-L1 antibodies alters its signaling activity. Because macrophages comprise one 
of the main PD-L1-expressing cell populations in tumors, it is crucial to elucidate whether PD-
L1 signals in macrophages and the effect of PD-L1 antibodies on altering macrophage phenotype 
in the tumor environment. To this end, we conducted studies described in Chapter 5 
characterizing the effects of PD-L1 antibody treatment on macrophage activation. We found that 
incubation of macrophages with PD-L1 antibody and with soluble CD80 resulted in macrophage 
proliferation, spreading, and activation. Treatment of macrophages with soluble PD-1 and 
untreated macrophages from PD-L1
-/- 
mice showed similar changes, but to a lesser extent. We 
also found that PD-L1 antibody treatment upregulated mTOR pathway signaling in 
macrophages, and gene expression profiling showed that macrophages treated with PD-L1 
antibodies were skewed towards a pro-inflammatory phenotype. We next used in vivo tumor 
models to assess the effect of PD-L1 antibody treatment on tumor macrophages. These studies 
revealed that PD-L1 antibody treatment increased numbers of tumor macrophages as well as 
	 vi	
their activation, and inhibited tumor growth was observed even in the absence of T cells. 
Furthermore, combined PD-1/PD-L1 antibody treatment of mice with established tumors 
resulted in complete tumor elimination in half of the animals. Overall, these findings implicate 
PD-L1 in constitutively suppressing mTOR pathway signaling in macrophages, and PD-L1 
antibody treatment removes this signal to produce activated, proliferating macrophages.  
In conclusion, we characterized the expression and regulation of PD-L1 by canine tumors 
and macrophages as well as a novel signaling role for PD-L1 in macrophages. Our studies 
provide strong rationale for the development of canine-specific PD-L1 antibodies for 
immunotherapy, and for the evaluation of PD-L1 expression levels in patients prior to the 
initiation of treatment. Furthermore, we identified a new mechanism for tumor-induced immune 
suppression mediated by upregulating PD-L1 expression by tumor macrophages in a murine 
system. This expression of PD-L1 by macrophages not only suppresses T cells responses in the 
tumor microenvironment, but we found that it also signals constitutively to maintain an anti-
inflammatory, pro-tumor macrophage phenotype. We further showed that treatment of 
macrophages with PD-L1 antibodies reverses this phenotype, and that the resulting population of 
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Review of the Literature 
 
The first immune checkpoint: CTLA-4. 
Tumor immunotherapy is a field that utilizes the ability of the immune system to 
recognize tumor cells based on their expression of tumor-related antigens. However, 
immunotherapeutic agents such as vaccines and cytokines have not been widely successful as 
single agents due to immunosuppression mediated by the exploitation of immune checkpoints in 
the tumor environment
1
. Under normal conditions, immune checkpoint molecules prevent 
autoimmunity and protect tissues from damage by downregulating the duration and magnitude of 
T cell responses. Two signals are required for full activation of T cells: binding of an antigen-
MHC complex with the T cell receptor (signal 1) and co-stimulation such as the binding of B7.1 
(CD80) or B7.2 (CD86) on an antigen-presenting cell (APC) to CD28 on the T cell (signal 2)
2,3
. 
TCR recognition of antigen without signal 2 leads to functional inactivation of antigen-specific T 
cells that cannot respond to further stimulation, a state known as T cell anergy
4
. Successful 
functioning of the adaptive immune system depends on a network of both stimulatory and 
inhibitory signals, but inhibitory checkpoint molecules are often overexpressed in the tumor 
environment. As a result, this system is dysfunctional in tumors, but specific targeting of these 
signaling pathways using antibodies can release the endogenous anti-tumor functions of tumor-
infiltrating immune cells.  
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, also known as CD152) was the 
first immune checkpoint molecule to be clinically targeted with monoclonal antibodies for the 
treatment of cancers. It is a co-inhibitory molecule that is induced during the early stages of 
2	
activation on T cells and competes with CD28 for binding B7 molecules on APC (signal 2)
5
. Not 
only does CTLA-4 have a higher affinity than CD28 for their ligands
6
, it can also sequester 
CD80 and CD86 from CD28 as well as remove these ligands from the surface of APC
7
. The 
level of CTLA-4 expression depends on the strength of the TCR signal, so that greater TCR 
stimulation leads to more CTLA-4 deposition on the surface of the T cell to dampen the signal 
and maintain a consistent level of T cell activation
3









As a strong negative regulator of immune responses, specific antibodies for blocking 
CTLA-4 were developed for their potent anti-tumor activity
9,10
. It was quickly discovered that 
full blockade of this receptor resulted in severe autoimmunity, but partial blockade and 
combinatorial therapies were found to be effective for inducing tumor regression and were safe 
in mouse models
9,11
. Two humanized CTLA-4 antibodies (ipilimumab and tremelimumab) were 
first developed, and clinical trials found both to induce immune-related toxicities in many 
patients
12-14
. However, toxicities related to treatment with ipilimumab were more clinically 
manageable and an impressive long-term survival benefit was demonstrated for a limited 
proportion of treated patients (18%)
15
. The FDA approved ipilimumab for the treatment of 
advanced melanoma in 2010, and a myriad of studies have since been underway to evaluate the 
effectiveness of combination therapies as well as to define biomarkers that predict clinical 
response to CTLA-4 antibody therapy
3
. The therapeutic benefits achieved with CTLA-4 antibody 
blockade re-ignited interest in the field of tumor immunotherapy, and the identification of new 
immune checkpoints and development of specific antibodies for those immune checkpoints 
became a top priority.  
3	
Programmed cell death 1 (PD-1) and its ligands. 
The second immune checkpoint to be targeted for the treatment of cancer consists of 
programmed cell death 1 (PD-1, also known as CD279) and its ligands PD-L1 (B7-H1, also 
known as CD274) and PD-L2 (B7-DC, also known as CD273). While CTLA-4 regulates T cell 
activation at the time of initial response to antigen, PD-1 is crucial in regulating effector T cell 
activity at the time of an inflammatory response in peripheral tissues
3
. PD-1 is a co-inhibitory 




 T cells, B 
cells, natural killer T (NKT) cells, monocytes, macrophages, and dendritic cells (DC)
16-18
. It is 
also highly expressed on Tregs, which enhances their proliferation to provide physiological 
homeostasis
19
. Ligation of PD-1 on T cells suppresses T cell activation and proliferation, and 
under normal conditions, maintains peripheral tolerance by limiting the activity of T cells during 
inflammatory responses
20-22
. Furthermore, expression of PD-1 on DC inhibits survival and pro-
inflammatory cytokine production
23,24
, and PD-1-deficient DC are less capable in inducing CD8
+
 
T cell activation and proliferation
25
. Engagement of PD-1 by its ligands also suppresses B cell 
production of antibodies and natural killer (NK) cell lytic activity
26,27
. These interactions help to 
avoid tissue damage caused by exuberant or prolonged inflammation
21,28
.  
PD-L1 and PD-L2 are distinct in both their expression patterns and regulation of the 
immune system
29
. PD-L1 is constitutively expressed by T and B cells, DC, macrophages, 
mesenchymal stem cells, bone marrow-derived mast cells, and non-hematopoietic cells
30
, and 
can be further upregulated by many cell types upon activation
17
. PD-L2 expression is more 
limited but is inducible on DC, macrophages, bone marrow-derived mast cells, and non-
hematopoietic tissues
17,29
. The main role of PD-L1 is to maintain T cell tolerance in peripheral 
tissues while PD-L2 suppresses T cell activation in lymphoid organs
29




, and both PD-L1 and PD-L2 appear to bind an unidentified co-stimulatory 
molecule on T cells
31,32
. Furthermore, T cells have been shown to physically acquire CD80 from 
APC after T cell activation
33-35
, and binding of PD-L1 to CD80 causes CD80 to deliver an 
inhibitory signal to T cells
21,22,27
.  
Increased expression of PD-L1 by tumor cells is an example of a phenomenon known as 
adaptive immune resistance
3
.  In the presence of high levels of PD-L1 expression in tumor 
tissues, tumor-infiltrating T cells (TILs) become functionally inactivated and lose the ability to 
effectively control tumor growth
36
. Chronic exposure to antigen without co-stimulation leads to 
T cell anergy and eventually T cell exhaustion, which is characterized by poor effector function, 
low proliferative activity, and the inability to persist as memory T cells
36
. PD-L1 expression on 
human tumor cells has been found to be negatively correlated with prognosis and patient survival 
in colon, cervical, pancreatic, breast, ovarian, renal cell, hepatocellular, non-small cell lung, 
melanoma, and esophageal cancers
37-46
. In mice, PD-L1 has been found to be expressed by 
ovarian, myeloma, lung, melanoma, and mammary cancers
47-50
, where it is involved with escape 
of the tumor cells from the immune system. Canine tumors have also been found to express PD-
L1, including melanoma, hemangiosarcoma, osteosarcoma, mastocytoma, and renal cell 
carcinoma
51-53
. In addition, myeloid cells such as tumor-associated macrophages commonly 
express PD-L1, and this is thought to be one of the mechanisms by which they exert 
immunosuppressive effects in the tumor environment
54-59
. While most studies focus on PD-L1 in 
the tumor environment, PD-L2 has also been found to be upregulated in B cell lymphomas
60
. 
Upregulated expression of PD-L1 in tumors has been found to be mediated primarily by 
IFN-γ produced by TILs in humans, mice, and dogs
61-64
. Other cytokines have also been found to 




. Furthermore, environmental factors such as hypoxia cause rapid upregulation of PD-L1 
expression by tumor cells, macrophages, and DC through HIF-1α
49
. The innate immune response 
has also been found to play a role in the regulation of PD-L1 expression in tumors. Toll-like 
receptor (TLR) expression is increased on many human tumors including colon, gastric, prostate, 
breast, ovary, and brain tumors, where signaling through the TLRs leads to upregulation of PD-
L1
66,67
. Furthermore, TLR2 and TLR4 ligands have been shown to protect acute myeloid 
leukemia blast cells from T cell killing through the induced expression of PD-L1
68
. Finally, some 
tumor cells possess “innate immune resistance” that does not depend on signals in the tumor 
environment
1
. For example, constitutive ALK signaling in lung cancer has been found to 
upregulate PD-L1 expression through STAT-3 signaling
69
 and loss of tumor suppressor PTEN 
results in increased PD-L1 expression by glioma
70
. Upregulation of PD-L2 in lymphomas has 




PD-1/PD-L1 blockade in tumors. 
The presence of TILs has been correlated with higher expression of both PD-1 and PD-
L1, which correlates with both poor prognosis and aggressive tumors
72,73
. PD-1 is expressed by 
most TILs, and these PD-1-expressing TILs are functionally impaired
74,75
. However, interrupting 
the PD-1/PD-L1 signaling pathway with therapeutic antagonistic antibodies can potently activate 
T cell responses to tumors. PD-1 antibody blockade in tumors increases the number of effector T 
cells, increases T cell proliferation and Th1 cytokine production (IFN-g, IL-2, TNF-α, IL-1 and 
IL-6), decreases Th2 cytokine production (IL-2 and IL-13), and decreases both the number and 
the suppressive activity of Tregs
29,76-78





The first PD-1 antibody to be tested in a human clinical trial was nivolumab. The study 
found up to 31% objective responses (of which 62% were durable greater than 1 year) in patients 
with advanced melanoma, non-small cell lung cancer, castration-resistant prostate cancer, renal 
cell cancer, and colorectal cancer
80,81
. Nivolumab has since been shown to be effective for 
treatment of several solid tumors both alone and in combination with CTLA-4 antibody 
ipilimumab
82,83
. Clinical trials in 2016 for another PD-1 antibody, pembrolizumab, showed 
overall response rates of 21-34% for advanced melanoma and up to 25% for non-small cell lung 
cancer, which led to FDA approval for these cancers
84
. To date, these PD-1 antibodies have been 
approved for treatment of melanoma, kidney cancer, non-small cell lung cancer, head and neck 
cancer, Hodgkin’s lymphoma, and urothelial cancer in humans
85
. Studies have also demonstrated 
the activity of PD-L1 antibodies in a variety of different cancer types
86-88
, and PD-L1 antibodies 
(atezolizumab and durvalumab) are now approved for treatment of lung cancer, bladder cancer, 
and urothelial cancer in humans
85-87
. Antibody blockade of PD-L1 has also been effective in 
combination with therapies such as radiation therapy, MAP kinase inhibition, 
immunovirotherapy, and administration of other checkpoint blocking antibodies such as CTLA-4 
antibodies
89-93
. Importantly, PD-1 and PD-L1 antibodies have been found to induce few adverse 




Future directions for immune checkpoint blockade. 
Unfortunately, most immunotherapeutic agents fail in randomized comparisons to other 
therapies in Phase III trials
95
. For example, an analysis of all clinical trials for PD-1/PD-L1 
antibodies to date found an overall pooled response rate of 24% for cancer patients with 
advanced stage, refractory, or sensitive to previous treatment
96
. However, this was still higher 
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than the response rates for standard chemotherapy and for treatment with ipilimumab (anti-
CTLA-4) for melanoma. This has led to many studies that focus on finding factors that predict 
response to treatment, with the goal of identifying patients who will benefit the most from these 
therapies. Potential biomarkers that have been widely studied include PD-1 and PD-L1 
expression in the tumor, tumor genomic features, tumor RNA expression signatures, tumor 
mutational burden, and immune cell infiltrates
97-101
. These markers have been found to be helpful 
for certain tumor types in predicting response, but none have been found to accurately predict 
response when applied to multiple tumor types. 
PD-L1 was studied as a potential biomarker when a correlation was found between PD-
L1 expression in the tumor and response to nivolumab
80
. Multiple studies agree that the density 
of PD-L1-expressing macrophages in tumors is predictive of the efficacy of both PD-1 and PD-
L1 antibody therapy
99,102,103
. For example, in some cases, response rates as high as 80% have 
been observed in patients where macrophages were positive for PD-L1 expression
99
. However, 
other studies have reported patients with PD-L1-negative tumors experiencing objective 
responses
104
 and a lack of correlation between PD-L1-positivity and improved response to PD-1 
therapy
82
. These discrepancies could be addressed by the fluid expression profile of PD-L1 in the 
tumor, as expression levels can change based on the previously described inflammatory signals. 
For example, PD-L1 expression can be induced in a tumor that was negative at the time of 
analysis. Furthermore, some PD-L1
+
 tumors solely express PD-L1 in the cytosol where it is not 
able to bind PD-1 on T cells
3
, leading to PD-L1 positivity that may not correlate to response to 
PD-1 blockade therapy. 
Recently, a study published in Science found a correlation that is being seen as a 
breakthrough in the search for a biomarker that can predict response to immune checkpoint 
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blockade. Mutation associated neoantigens (MANAs) arise during cellular transformation, and 
are thus tumor cell-specific. However, little is known concerning the nature of the tumor antigens 
that are targeted by T cells following activation by immune checkpoint blockade, and whether it 
is the mutation load or the identity of the mutations that allows tumor cells to be recognized as 
foreign by the immune system
105,106
. Mismatch repair (MMR)-deficiency in tumors has long 
been predicted to generate large numbers of MANAs, increasing the odds that some may be 
recognizable by the immune system
107-109
. The “breakthrough” study found that, indeed, MMR-
deficient cancers led to the accumulation of large numbers of MANAs that made patients 
responsive to PD-1 blockade (pembrolizumab)
110
. Data were collected from a pool of 86 patients 
with advanced MMR-deficient cancers spanning 12 tumor types, with objective responses found 
in 53% of patients and complete responses in 21% of patients. Interestingly, deep sequencing 
showed that all of the MANAs that were recognizable by T cells resulted from frameshift 
mutations, which is the mutation most characteristic of MMR-deficiency. Further work in this 
study showed that, in an evaluation of over 12,000 cancers representing 32 tumor types, up to 
8% of tumors were MMR-deficient. Fortunately, MMR-deficiency tests are widely available and 
should be considered for identifying patients that may benefit from PD-1 blockade, as it is a very 
promising pan-tumor biomarker for predicting response to immune checkpoint blockade. 
New immune checkpoint molecules have now been discovered, including T cell 
membrane protein 3 (TIM3), lymphocyte activation gene 3 (LAG3), and other members of the 
B7 family such as B7-H3 and B7-H4. TIM3 is overexpressed by Tregs in the tumor and is a 
marker of CD8
+
 T cell exhaustion
111
. LAG3 (CD223) is expressed by plasmacytoid DC, B cells, 
NKT cells, and exhausted CD8+ T cells, where it inhibits signaling in tumor-infiltrating CD8
+
 T 
cells upon binding to PD-1
112
. LAG3 is also expressed by Tregs, and antibody blockade of 
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LAG3 decreases their suppressive function
113
. Ligands B7-H3 and B7-H4 are expressed by both 
tumor cells and tumor-infiltrating cells, specifically by endothelial cells in the tumor vasculature 
(B7-H3) and tumor-associated macrophages (B7-H4)
114,115
. The receptors for these ligands are 
still unidentified, but they appear to be inhibitors of the immune response
115
. Tumor cells often 
express multiple inhibitory immune checkpoint ligands that bind their cognate receptors on TILs, 
which may explain the lack of clinical response in many patients to single antibody blockade. 
Therefore, current studies for immune checkpoint blockade largely focus on combination 
therapies that may target multiple inhibitory pathways, inhibitory and activating pathways, or 
multiple activating pathways.   
An important aspect of tumor immunotherapy to consider is the unique mechanisms-of-
action and kinetics of immune checkpoint antibody blockade. For example, response to CTLA-4 
antibody therapy can be delayed up to 6 months after treatment, during which lesions typically 
increase in size before regressing
3
. A combination of large international studies for ipilimumab 
detected four response patterns: immediate response, durable stable disease, response after tumor 
burden increase, and response in the presence of new lesions
116,117
. The delay in treatment 
response demonstrates the time needed to build a tumor-specific cellular immune response, and 
the increase in tumor size can reflect the influx of pro-inflammatory cells into the tumor
15
. 
Therefore, new tools for evaluation and new response criteria for trial endpoints is needed, as the 
conventional method of measuring time-to-progression or RECIST (Response Evaluation 




Several international initiatives have been facilitated by expert panels to systematically 




Based on the biological response to immunotherapy, three main events are being viewed as 
potential clinical trial endpoints: early immune activation and T cell proliferation, anti-tumor 
effects mediated by activated immune cells, and delayed effect on patient survival
122
. Therefore, 
the considerations for these endpoints are as follows: minimize variability in T cell assays to 
establish reproducible measurements of cellular immune response, adapt RECIST to the clinical 
pattern of antitumor response for immunotherapeutic agents (to be called irRC, or immune-
related response criteria), and use appropriate statistical methods for both trial design and 




Immune Regulation of Canine Tumor and Macrophage PD-L1 Expression 
 
Summary. 
High expression of programmed cell death receptor ligand 1 (PD-L1) on tumor cells has 
been associated with immune escape in human and murine cancers, but little is known regarding 
the expression and regulation of PD-L1 by cancers in dogs. Therefore, 14 canine tumor cell lines 
were evaluated for constitutive PD-L1 expression and for responsiveness to immune stimuli. We 
found PD-L1 was expressed constitutively on all canine tumor cell lines evaluated, though the 
levels of basal expression were variable. Significant upregulation of PD-L1 by all cell lines was 
observed following IFN-γ and a TLR3 ligand treatment. In contrast, canine macrophages did not 
constitutively express PD-L1 but were also responsive to IFN-γ. These findings suggest that 
most canine tumors express PD-L1 constitutively and that both innate and adaptive immune 
stimuli can further upregulate PD-L1 expression. Therefore, upregulation of PD-L1 expression 
by cancers in response to cytokines such as IFN-γ may represent an important mechanism of 
tumor-mediated T cell suppression in dogs as well as in humans.  
 
Background. 
In recent years, it has become evident that there is a critical need for animal models that 
more accurately depict human biology and disease progression. Thus, the field of comparative 
oncology draws from the premise that veterinary patients with naturally-occurring cancers 
provide an invaluable source of knowledge that can be applied to human biology and disease
123
. 
When the canine genome was sequenced and compared to the human genome, the two were 
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found to have over 80% genetic similarity
124,125
. This leads to genetic drivers for the 
development of cancers, molecular and clinical presentation of disease, and response to treatment 
that are often identical between canine and human
126-130
. Furthermore, there is great genetic 
diversity even among closely related dog breeds
131
. This is crucial for biomedical research, as 
research mice are inbred to be genetically identical and live in a highly-regulated environment. 
In contrast, dogs differ greatly in terms of genetics, living environment, diet, and lifestyle, which 
can more accurately model the differences between humans. These variables allow for naturally 
occurring disease in both species that can be more directly compared instead of inbred mice that 
have artificially been injected with tumor cells to initiate tumor growth.   
The success of PD-1 and PD-L1 immunotherapy in the treatment of human cancers has 
prompted the research and development of canine-specific immunotherapies. Recently, canine 
PD-1 and PD-L1 were molecularly characterized, and the corresponding genes were found to be 
conserved among dog breeds
51
. We, and others, have reported that PD-1 and PD-L1 antibodies 
can activate canine T cells, stimulating proliferation and cytokine production
132,133
. In addition, a 
recent report describes the first use of a canine chimeric PD-L1 antibody in dogs with cancer, 
with anti-tumor responses observed in several treated animals
133
. 
However, the expression of PD-L1 by a broad panel of canine tumor types has not been 
previously investigated, nor has the regulation of canine PD-L1 expression on tumor cells been 
studied. Therefore, the purpose of the current study was to investigate PD-L1 expression by a 
series of canine tumor cell lines and to determine how PD-L1 expression on these cells was 
regulated by IFN-γ and also by TLR ligands. Because PD-L1 is also known to be expressed by 
tumor-infiltrating macrophages in humans, we also investigated the expression of PD-L1 by in 
vitro generated canine macrophage cultures, and the effects of cytokines on macrophage PD-L1 
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expression. We hypothesized that both tumor cell and macrophage PD-L1 expression would be 
primarily regulated by IFN-γ, because this cytokine is known to regulate PD-L1 expression by 
tumor cells in humans, mice, and dogs
61-64
. A recently developed canine PD-L1 antibody was 
used in this study, and expression of PD-L1 by canine tumor cell lines was assessed by flow 
cytometry and by immunocytology. The tumor PD-L1 response to treatment with recombinant 
canine IFN-γ and to TLR ligands was also assessed, as was the PD-L1 response to cytokine-
enriched conditioned medium from activated canine T cells.  
 
Materials and Methods. 
Cell lines. Fourteen different canine tumor cell lines were evaluated in this study. All cell lines 
were validated and screed to be genetically unique
134
. Melanoma (MEL) cells included Talsky, 
Shadow, and Jones (Colorado State University - CSU). Canine osteosarcoma (OS) cells included 
Abrams (CSU), D17 (ATCC), and McKinley (CSU). Canine hemangiosarcoma (HSA) cells 
included DEN-HSA (University of Wisconsin) and SB (University of Minnesota). The Bliley 
cell line was a transitional cell carcinoma (TCC) from CSU while the Oswald cell line was a T 
cell lymphoma (LSA) from Ohio State University - OSU. The C2 cell line was a mast cell tumor 
(MCT) from the University of California, San Francisco. The CTAC cell line was a thyroid 
cancer (TA) from Auburn University, and canine histiocytic sarcomas (HS) included Nike (CSU) 
and DH82 (ATCC). 
 
Tumor Cell culture. Tumor cells were grown in MEM medium (Gibco, Grand Island, NY) 
supplemented with 10% FBS (Atlas Biologicals, Fort Collins, CO) and 5% CTM (10,000 ug/mL 
Pen/Strep, 200 mM L-glutamine, 10 mM essential amino acids without L-glutamine, 10 mM 
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non-essential amino acids, and 7.5% bicarbonate solution (all from Gibco). The cells were 
cultured in standard plastic tissue culture flasks (Cell Treat, Shirley, MA) and strongly adherent 
cells were harvested by treatment with 0.25% Trypsin/1mM EDTA (Gibco) followed by 
Trypsin/EDTA inactivation with media. Viability of the cells was determined using 0.4% Trypan 
blue stain (Gibco) for dead cell exclusion. 
After the tumor cells were harvested from culture, 1.0 x 10
5
 viable cells were plated in 
24-well polystyrene cell culture plates (Falcon, Durham, NC). The cells were then treated with 
cytokines, supernatants from Concavalin A (ConA) activated peripheral blood mononuclear cells 
(PBMCs), or TLR ligands for 24 hours at 37°C. The supernatants were generated by incubating 
primary canine PBMCs in 10 ug/ml conA (Sigma-Aldrich, St. Louis, MO) overnight, collecting 
the supernatants, and centrifuging to remove the remaining cells out of the supernatants. For 
analysis, the cells were trypsinized and washed with media before transfer to a round bottom 96-
well plate (Falcon) for immunostaining. The wells were washed with FACS buffer and 
centrifugation to collect the cell pellets, and the cells were stained for flow cytometry. 
 
Macrophage culture. Canine macrophages were derived from peripheral blood monocytes 
obtained from healthy dogs. Briefly, PBMCs were obtained using LSM Lymphocyte Separation 
Medium (MP Biomedicals, Solon, OH) and plated on fibronectin-coated wells in 24-well 
polystyrene cell culture plates (fibronectin was obtained from Sigma-Aldrich). Non-adherent 
cells were removed after 18 hours in culture and adherent monocytes were cultured for 7 days in 
10 ng/ml human M-CSF (Peprotech, Rocky Hill, NJ) in DMEM medium (Gibco) supplemented 
with 10% FBS. The growth media was changed and fresh huM-CSF (10 ng/ml) was added every 
2 days. 
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Cytokines and TLR reagents. Recombinant canine IFN-γ was obtained from R&D Systems, 
Minneapolis, MN and titrated at 0.1, 1, 10, and 100 ng/ml in tumor culture medium. Tumor cells 
were cultured in the presence of IFN-γ in complete medium for 24h prior to analysis of PD-L1 
expression. For the majority of studies, IFN-γ was used at 10 ng/ml based on the results of the 
titration studies. Polyinosinic:polycytidylic acid, Poly(I:C), was purchased from Invivogen (San 
Diego, CA) and was used at 10 ug/ml. Plasmid DNA (pDNA) was produced by Juvaris 
Biotherapeutics, Inc (Pleasanton, CA) and used at 10 ug/mL. Lipopolysaccharide, LPS (E.coli 
serotype 0111:B4), was obtained from Sigma-Aldrich and used at 1 ug/ml. R848 from Invivogen 
was used at 10 ug/ml. These concentrations were chosen based on the working concentration 
ranges suggested by the manufacturers. The activity of these TLR agonists was verified in mouse 
studies, and their activity in stimulating canine TLRs was assessed by stimulation of canine 
monocyte-derived macrophages and measurement of IL-6 secretion with an ELISA (data not 
shown).  
 
Antibodies. A murine anti-canine PD-L1 monoclonal antibody (clone 4F9) was used in these 
studies to detect canine PD-L1 expression. This antibody was developed by Merck Animal 
Health (Millsboro, DE) and was used for flow cytometry, immunofluorescence staining, and 
Western blotting. An isotype matched, irrelevant antibody was used at the same concentration 
(eBioscience, San Diego, CA). Mouse mAbs were detected using a donkey anti-mouse 
secondary (Jackson ImmunoResearch, West Grove, PA). Mouse anti-human CD11b (clone 
Bear1) was obtained from Immunotech by Beckman Coulter (Marseilles, France) and used for 
used for flow cytometric evaluation of primary canine macrophages. A polyclonal goat anti-
canine IFN-γ antibody from Novus Biologicals (Littleton, CO) was used at 5 ug/ml to neutralize 
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IFN-γ in activated PBMC-conditioned media for 30 minutes prior to treating the tumor cells, and 
an irrelevant control was a polyclonal goat IgG antibody from Jackson ImmunoResearch, used at 
the same concentration. 
 
Western Blot. A standard Western blotting protocol from (Bio-Rad, Hercules, CA) was followed. 
Briefly, the tumor cells were harvested by scraping, then lysed in the presence of protease 
inhibitors (Thermo Fisher Scientific, Waltham, MA) and the protein concentration was 
determined using a Pierce BCA protein assay kit (Thermo Fisher Scientific). Samples were 
prepared under non-reducing, denaturing (boiled) conditions, and 20 ug total protein was loaded 
into a 4-15% gradient mini PROTEAN TGX BioRad gel. 5% non-fat dry milk was used for 
blocking and 4F9 mAb was used to probe for PD-L1 protein, followed by a peroxidase-
conjugated donkey anti-mouse secondary. The blots were visualized using BioRad Clarity 
Western ECL Substrate.  
 
Flow cytometry. Tumor cells were harvested from culture using 0.25% Trypsin/1mM EDTA 
(Gibco), washed with PBS, and incubated 10% normal donkey serum (Jackson 
ImmunoResearch) to reduce non-specific binding of antibodies. To detect expression of canine 
PD-L1 on the surface of the cells, appropriately diluted PD-L1 4F9 mAb or concentration 
matched isotype control MOPC-21 mAb (BioXcell, West Lebanon, NH) were added to tumor 
cells for 20 minutes at room temperature. The cells were then washed in FACS buffer and 
incubated with biotin-conjugated donkey-anti-mouse (Jackson ImmunoResearch) antibody 
followed by washing and then incubation with streptavidin-conjugated PE (eBioscience, San 
Diego, CA). After a final wash, cells were resuspended in FACS staining buffer and 7-AAD 
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viability dye (eBioscience) was added for dead cell exclusion. The cells were evaluated for PD-
L1 expression using a Beckman Coulter Gallios flow cytometer (Brea, CA), and data was 
analyzed using FlowJo Software (Ashland, OR). 
Monocyte-derived macrophages were detached from tissue culture plastic with 2mM 
EDTA in ice-cold PBS for 30 minutes on ice followed by gentle pipetting to wash off cells from 
the plate. The cells were blocked with 5% normal donkey serum and dog serum before 
incubating with 4F9 (or isotype control) along with CD11b, and were afterwards stained 
following the same protocol as the tumor cells.  
 
Immunofluorescence imaging. Tumor cells were cultured on glass coverslips overnight, with or 
without IFN-γ (10 ng/ml). The next day, the coverslips were washed, fixed in ice-cold acetone 
for 10 minutes, and rehydrated in 1X PBS prior to staining. After blocking with 5% donkey 
serum and Streptavidin block (Vector Laboratories, Burlingame, CA), 4F9 or isotype antibody 
with Avidin block (Vector Laboratories) was added in appropriate concentrations. This was 
followed by biotin-conjugated donkey-anti-mouse IgG and streptavidin-conjugated Cy-3 
(Invitrogen). Lastly, the cells were stained with DAPI (Molecular Probes, Eugene, OR) and 
mounted onto Superfrost slides (VWR, Radnor, PA) with Fluoromount Aqueous Mounting 
Medium (Sigma-Aldrich). 
Primary tumor tissues were frozen in OCT (Optimal Cutting Temperature compound) 
and cut to a thickness of 5 microns. After fixing in ice-cold acetone for 5 minutes, they were 
rehydrated with 1X PBS and stained the same way as the tumor cell lines grown on coverslips. 
 
18	
RT-PCR. Total RNA was isolated from canine tumor cell lines with and without IFN-γ treatment 
using an RNeasy Mini Kit (Qiagen, Frederick, MD), and this was transcribed into cDNA using a 
QuantiTect Reverse Transcription Kit (Qiagen). SYBR Green-based PCR (Bio-Rad, Berkeley, 
CA) was conducted with the following primer sequences to amplify PD-L1 mRNA (Integrated 
DNA Technologies, Coralville, IA): 5’-CCG CCA GCA GGT CAC TT-3’ (forward) and 5’ TCC 
ATT GTC ACA TTG CCA CC-3’ (reverse). This primer pair was validated with an 
amplification efficiency of 102% and an R
2
 value of 0.991. Data analysis was based on the fold 
change = 2
-ΔCt 
method, with normalization of the data to the GAPDH housekeeping gene. 
Relative quantification was calculated using the average value of duplicate samples.   
 
Results. 
PD-L1 expression and responsiveness to IFN-γ. The expression of PD-L1 was assessed on 14 
distinct canine tumor cell lines, using flow cytometric analysis. We found all 14 expressed PD-
L1 under basal conditions, with the two histiocytic sarcoma cells lines expressing the highest 
level (Figure 2.1). The cell lines with the lowest levels of surface PD-L1 expression were the 
lymphoma and two hemangiosarcoma cell lines. We also assessed the intracellular expression of 
PD-L1 by fixing and permeabilizing tumor cells on coverslips and assessing PD-L1 expression 
microscopically (Figure 2.2). We found that all 4 tumor cell lines screened expressed PD-L1 
intracellularly as well as extracellularly, when staining intensity was compared to that of the 
isotype control antibody. 
IFN-γ has been reported to regulate PD-L1 in human and mouse systems
62,64
. Therefore, 
the effects of canine rIFN-γ on PD-L1 expression on our canine tumor cell lines was assessed. 
We found that there was a titratable effect of IFN-γ on PD-L1 upregulation (Figure 2.3A). A 
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Figure 2.1 PD-L1 expression by 14 canine tumor cell lines. Canine tumor cells were cultured 
in 24-well plates overnight and stained the following day for PD-L1 expression by flow 
cytometry. The cells were incubated with the appropriately matched concentration of irrelevant 
isotype (gray filled line) or PD-L1 antibody (bold white line) and the data were analyzed using 
FlowJo Software. PD-L1 expression was determined with respect to the mean fluorescence 




Figure 2.2 PD-L1 expression by canine tumor cell lines as assessed by immunofluorescence 
imaging. Canine melanoma, osteosarcoma, transitional cell carcinoma, and histiocytic sarcoma 
cells were grown as monolayers on glass coverslips and stained for immunofluorescence with 
either PD-L1 or irrelevant isotype antibody (red) and a DAPI nuclear stain (blue). The coverslips 
were mounted on glass slides and the images were obtained with the same microscope settings to 
show the relative intensity of PD-L1 staining between tumor cell lines.  
 
mid-range concentration of IFN-γ (10 ng/ml) was then selected for most of the remaining IFN-γ 
studies. This concentration of IFN-γ was found to upregulate PD-L1 expression by all the tumor 
cell lines except the B cell lymphoma cell lines, though to differing degrees depending on the 
cell line (Figure 2.3B). For example, histiocytic sarcoma cells were the most responsive to IFN-
γ stimulation, upregulating PD-L1 significantly more than other cell lines when comparing MFI 
between unstimulated and IFN-γ treated cells (p-value < 0.001). qRT-PCR for 5 different cell 
lines with and without IFN-γ treatments showed that, in general, Pdl1 transcript levels increased 
after exposure of the cells to IFN-γ but do not correspond to the amount of PD-L1 protein 
expressed by the cells when compared between tumor cell lines (Figure 2.4). These data were 
also shown using immunocytology, where PD-L1 expression was increased in both locations 
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after treatment with IFN-γ (Figure 2.5). Finally, the 4F9 antibody was shown to bind a protein of 
the correct molecular weight of glycosylated PD-L1, 50 kDA, and its expression was increased 
after treatment of histiocytic sarcoma cells with IFN-γ (Figure 2.6). 
 
Cytokine regulation of PD-L1. The effect of other immune-regulatory cytokines on PD-L1 
expression was also investigated. Because T cell cytokines other than IFN-γ (eg, IL-4, GM-CSF, 
TGF- β) have been shown to upregulate PD-L1 expression on different murine cell types
30,65
, we 
were interested to determine the net effect of all cytokines produced by activated T cells on 
canine tumor PD-L1 expression. A mixture of different T cell cytokines was generated from in 
vitro activated canine PBMC, using ConA stimulation. The canine IFN-γ concentration in the 
supernatants of conA stimulated PBMC was found to be 8 ng/ml by ELISA (data not shown). 
The T cell cytokine mixture was then evaluated for upregulation of tumor PD-L1 expression. We 
found that the T cell cytokine mixture strongly upregulated PD-L1 expression (Figure 2.7A), 
above levels observed following incubation with equivalent amounts of 8 ng/ml IFN-γ alone 
(Figure 2.7B). These findings suggested that IFN-γ in combination with other T cell cytokines 
can stimulate even greater upregulation of tumor PD-L1 expression. When IFN-γ was 
neutralized in the supernatants of conA stimulated PBMCs, PD-L1 upregulation by histiocytic 
sarcoma cells was markedly inhibited (Figure 2.8). These findings suggest that IFN-γ is the 
primary cytokine produced by activated canine T cells that is responsible for upregulating PD-L1 
expression on canine tumor cells and macrophages, though other T cell derived cytokines appear 




Figure 2.3 Effect of IFN-γ stimulation on PD-L1 expression by canine tumor cells. (A) 
Titration of IFN- γ. Canine melanoma, osteosarcoma, transitional cell carcinoma, and histiocytic 
sarcoma cells were cultured with 0 (gray line), 1 (dotted line), 10 (dashed line), or 100 ng/ml 
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rcIFN-γ (bold line) in media overnight. The cells were then immunostained for PD-L1, and flow 
cytometry was used to compare the mean fluorescence intensity of each treatment group. This 
titration experiment was conducted 4 times, with similar results each time. (B) Treatment of all 
canine tumor cell lines with 10 ng/ml IFN- γ. Tumor cell lines were treated with 10 ng/ml rcIFN-
γ overnight and stained with an irrelevant isotype antibody (gray filled line) or PD-L1 antibody 
(unstimulated is the dotted line and IFN-γ treated is the bold line) and analyzed by flow 







































































Figure 2.4. qRT-PCR of canine tumor cell lines with and without IFN-γ treatment. 5 canine 
tumor cell lines were cultured overnight in regular media or media with IFN-γ. RNA was 
extracted for qRT-PCR, and Ct values were normalized to the housekeeping gene GAPDH. Fold 







Figure 2.5 Effect of IFN-γ stimulation on PD-L1 expression by canine tumor cell lines, as 
assessed by immunofluorescence imaging. Canine melanoma, osteosarcoma, transitional cell 
carcinoma, and histiocytic sarcoma cells were grown as monolayers on glass coverslips in media 
alone or with10 ng/ml rcIFN-γ overnight. The next day they were stained for 
immunofluorescence with either PD-L1 or irrelevant isotype antibodies (red) and a DAPI nuclear 
stain (blue). The coverslips were mounted on glass slides and the images were obtained with the 
same microscope settings to show the relative intensity of PD-L1 staining between unstimulated 






Figure 2.6 Western Blot of PD-L1 expression by HS1 cells with and without IFN-γ 
treatment. Equal numbers of canine histiocytic sarcoma cells were cultured overnight with and 
without IFN-γ treatment. They were collected, lysed, and 20 ug total protein was loaded into a 
boiled gel for electrophoresis under non-reducing, denaturing conditions. The gel was blotted 




Figure 2.7 Effect of cytokines produced by concanavalin A activated canine T cells on 
tumor PD-L1 expression. (A) Dilutions of supernatants from conA-stimulated PBMCs. Canine 
melanoma, osteosarcoma, transitional cell carcinoma, and histiocytic sarcoma cells were exposed 
to 4 dilutions of supernatants from ConA stimulated PBMC overnight. Groups include no ConA 
supernatant (light gray filled line), 1:100 dilution (dotted line), 1:10 dilution (dashed line), and 
1:1 dilution (bold line). The cells were then harvested and stained with PD-L1 for flow 
cytometric analysis as previously described. This experiment was repeated 4 times. (B) 
Supernatants from conA-stimulated PBMCs and IFN-γ. The same tumor cell lines tested in (A) 
were incubated overnight with media only (gray filled line), 4 ng/ml rcIFN-γ (dotted line), or a 
1:1 dilution of these supernatants (bold line) and stained for PD-L1 expression. These data are 





Figure 2.8 IFN-γ neutralization in supernatants from conA-stimulated PBMCs. Canine 
histiocytic sarcoma cells were cultured overnight in regular media, conditioned supernatants 
from conA-stimulated PBMCs, and conditioned supernatants with an IFN-γ neutralizing 
antibody or its corresponding isotype antibody. They were then harvested and stained for PD-L1 
upregulation by flow cytometric analysis. 
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Regulation of PD-L1 by innate immune stimuli. We also tested the effects of TLR activation on 
tumor expression of PD-L1. The canine tumor cell lines were treated with ligands for TLR3 
(pIC), TLR9 (pDNA), TLR4 (LPS), and TLR7/8 (R848) for 24 hours and their PD-L1 
expression level was assessed by flow cytometry. As shown in Figure 2.9, we found that 
treatment with pIC consistently upregulated PD-L1 on all 4 cell lines screened (p-value = 0.048). 
However, only histiocytic sarcoma was responsive to all 4 TLR ligands with respect to 
upregulation of PD-L1 expression (p-value < 0.001).  
 
 
Figure 2.9 PD-L1 expression response to tumor cell activation with TLR ligands.  Canine 
melanoma, osteosarcoma, transitional cell carcinoma, and histiocytic sarcoma cells were treated 
with media only (gray filled line), pDNA (long dashed line), LPS (dotted line), poly(I:C) (bold 
line), or R848 (dashed line) overnight before analysis for PD-L1 expression by flow cytometry. 
This experiment was repeated 6 times. 
 
PD-L1 expression by monocyte-derived macrophages. Studies in rodents and humans have found 
that PD-L1 is also expressed by myeloid cells, especially macrophages, in addition to tumor 
cells
56,135
. Therefore, canine monocyte-derived macrophages were evaluated for PD-L1 
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expression after overnight incubation in media to select for adherent cells (Figure 2.10A) and 
after 7-day culture in human M-CSF (Figure 2.10B). Macrophages were found to express low to 
negative levels of PD-L1 after overnight culture. Moreover, the macrophages did not express 
PD-L1 after 1 week in culture with human M-CSF. However, the macrophages did respond to 
IFN-γ stimulation, as their PD-L1 expression increased significantly (P value = 0.001) after 
overnight treatment with IFN-γ. 
 
Figure 2.10 PD-L1 expression by canine monocyte-derived macrophages. Primary canine 
monocytes were cultured as described in Methods, then detached and immunostained with PD-
L1 antibody for analysis by flow cytometry for PD-L1 expression. (A) Primary Canine 
monocytes plated overnight. (B) Macrophage enrichment with huM-CSF. Primary canine 
monocytes were cultured in huM-CSF for one week to enrich for macrophages (Isotype is light 
gray filled and PD-L1 is bold). (C) Monocyte-derived macrophages stimulated with IFN-γ. 
Cultured cells from (B) were treated overnight with rcIFN-γ (Isotype is light gray filled, baseline 
PD-L1 is dotted, and IFN-γ treated is bold). These data are representative of staining from 3 
different dogs. 
 
PD-L1 expression on primary tumors. Expression of PD-L1 by a canine histiocytic sarcoma 
tumor biopsy was assessed to compare the staining intensity to in vitro histiocytic sarcoma cell 
lines. These tumor biopsy studies are being extended by a larger study currently in progress, 
where we are currently assessing PD-L1 expression by a panel of canine tumor biopsies 
(Faulhaber, et al., manuscript in preparation). Fresh frozen tumor samples were immunostained 
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for PD-L1 expression. PD-L1 was found to be highly expressed in the histiocytic sarcoma tumor 




Figure 2.11 PD-L1 expression by canine histiocytic sarcoma tissue biopsy.  Tumor biopsy 
was obtained from a dog with malignant histiosarcoma and imbedded in OCT and cryosectioned.  
Tumor tissues were immunostained as described in Methods and imaged by confocal 
microscopy.  Intense expression of PD-L1 (red) was observed throughout the tumor section.  Cell 
nuclei were stained with DAPI (blue).  
 
Discussion. 
In this study we observed that all the canine tumor cell lines evaluated expressed 
detectable levels of PD-L1 under basal (ie, unstimulated) conditions. Moreover, all the canine 
tumor cell lines were highly responsive to treatment with IFN-γ with the histiocytic sarcoma 
lines being the most responsive. In addition, the histiocytic sarcoma cell lines were also the most 
responsive to stimulation with a variety of TLR agonists. The increased expression of PD-L1 and 
increased overall sensitivity to activation with immune stimuli may be related to the origin of the 
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histiocytic sarcoma cell lines from cells of the macrophage/dendritic cell lineage, which are 
normally very sensitive to activation by TLR ligands
136,137
.  
IFN-γ is recognized as the principle cytokine that upregulates PD-L1 expression on many 
tumor types in human and mouse models
62,64
. Recently, it was reported that IFN-γ also  
upregulates PD-L1 expression on certain canine tumor lines when used at a high 
concentration
51
.We observed that all of the canine tumor cell lines evaluated upregulated PD-L1 
expression in response to IFN-γ in a dose-dependent manner. Moreover, we also found that 
cytokine-rich supernatants from activated canine T cells also induced a significant increase in 
PD-L1 expression over that induced by treatment with IFN-γ alone. This finding suggests the 
presence of other immune-modulating cytokines may further upregulate PD-L1 expression by 
canine tumor cells, or cytokines that may increase the activity of IFN-γ in inducing PD-L1 
upregulation. It has been reported that IL-4 and TNF-α together can synergistically induce PD-
L1 expression by human renal cell carcinoma cells
65
. Thus, IL-4 and TNF-α from T cells may 
potentially be active in upregulating PD-L1 expression on canine tumor cells. 
Human tumor cells have been found to express various TLRs and to upregulate PD-L1 
following activation by ligands for TLR2, TLR3 and TLR4
66,68
. We found that the TLR3 agonist 
poly(I:C) induced upregulation of PD-L1 on melanoma, osteosarcoma, transitional cell 
carcinoma, and histiocytic sarcoma cells, while all 4 TLR agonists evaluated (ie, agonists for 
TLR3, TLR4, TLR7/8, and TLR9) triggered upregulated PD-L1 expression on canine histiocytic 
sarcoma cells. These data suggest that the innate immune responses may also play a role in 
regulating canine tumor PD-L1 expression.  
For the cell lines evaluated in this study, PD-L1 expression was observed be located on 
both the cell membrane and within the cytoplasm. This is somewhat different than the location of 
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PD-L1 expression on human tumor cells, which has been reported to be expressed solely on the 
plasma membrane of some tumor cells and in the cytoplasmic compartment of others, even 
within the same tumor sample
138
. However, other studies have demonstrated both cytoplasmic 
and surface staining in the same cells
139,140
. Our findings also add additional tumor cell lines and 
mechanistic insights to a previous study that evaluated the presence or absence of PD-L1 
expression on canine tumor cell lines
51
.  
Tumor-associated macrophages (TAM) comprise a large population of tumor stromal 
cells
135
. We did not observe constitutive PD-L1 expression on early cultures of canine 
macrophages, which is in contrast to findings from a prior study in mice
30
. However, we did find 
that treatment with IFN-γ significantly upregulated PD-L1 expression by cultured canine 
macrophages, which is in agreement with the previous rodent study. It should also be noted that 
the source of macrophages was different in our study (blood) versus the rodent studies 
(peritoneal cavity), which may also account for the differences in constitutive PD-L1 expression. 
IFN-γ is widely accepted to be a pro-inflammatory cytokine. However, it has been shown that it 
also plays a role in inducing the production of anti-inflammatory cytokines such as IL-1Ra and 
IL-18BP
141
. These counter-regulatory, immune-suppressive activities allow IFN-γ to protect the 
host from tissue damage caused by uncontrolled inflammation. Based on these data, the 
induction of PD-L1 expression may be another way by which IFN-γ acts to control the duration 
and intensity of host inflammatory responses. 
 Upregulated expression of PD-L1 by tumor cells is an example of a phenomenon known 
as adaptive immune resistance
3
. PD-L1 expression by tumor cells may therefore be useful as a 
marker of the level of adaptive immune resistance exhibited by tumors
48,142
, as well as a 
predictor of the effectiveness of PD-1/PD-L1 blockade for cancer immunotherapy
55,80
. It has 
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recently been shown that the use of PD-L1 blocking antibodies enhances cytokine secretion by 
peripheral blood mononuclear cells and tumor-infiltrating cells in vitro in dogs
51
, suggesting that 
PD-L1 blockade may be an effectiveness means of immunotherapy for certain canine tumors. 
Studies are currently underway in our laboratory assessing the patterns of PD-L1 expression by 
canine tumor cells in vivo (using tumor biopsies) to determine the degree of PD-L1 expression 
heterogeneity and tumor-type association (Faulhaber E, manuscript in preparation). The 
tremendous potential for checkpoint molecule blockade, based on the results of recent human 
clinical trials
97,143
, suggests that such an approach also has considerable merit for treatment of 




Checkpoint Molecule Expression by B and T cell Lymphomas in Dogs 
 
Summary. 
Immunotherapies targeting checkpoint molecule programmed death receptor-1 (PD-1) 
protein were shown to be effective for treatment of Hodgkin lymphoma in people, but little is 
known about the expression of PD-1 or its ligand PD-L1 by canine lymphoma. Therefore, flow 
cytometry was used to analyze expression of PD-1 and PD-L1 in canine lymphoma, using fine-
needle aspirates of lymph nodes from 34 dogs with B cell lymphoma (BCL), 6 dogs with T cell 
lymphoma (TCL), and 11 dogs that had relapsed. Furthermore, fine-needle aspirates were 
obtained from 17 healthy dogs for comparison. Lastly, the impact of chemotherapy resistance on 
expression of PD-1 and PD-L1 was assessed in vitro. These studies revealed increased 
expression of PD-L1 by malignant B cells compared to normal B cells. In the case of TCL, 
tumor cells and normal T cells both showed low to negative expression of PD-1 and PD-L1. In 
addition, tumor infiltrating lymphocytes from both BCL and TCL had increased expression of 
both PD-1 and PD-L1 expression compared to B and T cells from lymph nodes of healthy 
animals. In vitro, chemotherapy-resistant BCL and TCL cell lines exhibited increases in both 
PD-1 and PD-L1 expression, compared to non-chemotherapy selected tumor cells. These 
findings indicate that canine lymphomas exhibit upregulated checkpoint molecule expression, 






Lymphoma is one of the most common malignancies in dogs, accounting for up to 24% 
of all diagnosed canine neoplasms
144
. Furthermore, evidence suggests that the incidence of 
naturally-occurring lymphomas in dogs is increasing
145
. The most widely used cytotoxic 
chemotherapy protocols to date generate remission times of 1-1.5 years, but virtually all dogs 
eventually relapse and require treatment with rescue cytotoxic chemotherapy protocols
146-148
. 
Thus, an immunotherapy that could be combined with chemotherapy, or administered after 
remission induced by chemotherapy, could have a significant impact on survival in dogs with 
lymphoma. There have been several trials evaluating cancer vaccines in dogs with lymphoma, 




The goal of our study was to gain a better understanding of the biology of two key 
checkpoint molecules (PD-1 and PD-L1) in dogs with lymphoma, and determine how 
chemotherapy resistance may affect expression levels. To address these questions, we obtained 
lymph node aspirates from 17 healthy dogs and from 51 dogs with lymphoma. Samples were 
evaluated by flow cytometry to compare PD-1 and PD-L1 expression by malignant and healthy 
B and T cells. In addition, the effects of chemotherapy resistance on expression of checkpoint 
molecules by canine lymphoma cells was assessed. Our hypothesis was that expression of both 
PD-1 and PD-L1 would be increased on malignant B and T cells compared to healthy B and T 
cells, and that chemotherapy resistance would lead to further increases in expression of these 
checkpoint molecules. The findings reported here indicate overall upregulation of checkpoint 
molecule expression by B cell lymphomas and by tumor-infiltrating lymphocytes in dogs, and 
suggest a connection with chemotherapy resistance and increased PD-1 and PD-L1 expression. 
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Materials and Methods. 
Clinical samples and cell lines. Fine needle aspirates (FNAs) were obtained from the lymph 
nodes of 17 healthy dogs and from lymph nodes of 34 dogs with untreated B cell lymphoma 
(BCL), 6 dogs with untreated T cell lymphoma (TCL), 9 dogs with relapsed BCL, and 2 dogs 
with relapsed TCL. Control lymph node FNAs were obtained from dogs owned by hospital staff, 
and the animals were deemed healthy based on a normal physical exam and normal blood work 
conducted in the last year. Tissue sampling procedures were kept consistent for all samples and 
were obtained by the same hospital personnel. All applicable international, national, and 
institutional guidelines for the care and use of animals were followed. Ages for healthy dogs 
ranged from 1 to 12 years and for lymphoma dogs ranged from 3 to 14 years (the mean age 
difference between the two groups was not statistically significant, as shown in Figure 3.1). 
Validated canine lymphoma cell lines CLBL1 (BCL
152
) and Oswald (TCL
153
) were 
maintained in MEM medium (Gibco, Grand Island, NY) supplemented with 10% FBS (Atlas 
Biologicals, Fort Collins, CO) and 5% CTM (10,000 ug/mL Pen/Strep, 200 mM L-glutamine, 10 
mM essential amino acids without L-glutamine, 10 mM non-essential amino acids, and 7.5% 




Figure 3.1. Fine needle aspirates were obtained from the lymph nodes of 17 healthy dogs, 41 
untreated lymphoma patients, and 10 relapsed lymphoma patients. Ages of the dogs were 
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graphed and data are presented as mean ± SEM of the dog ages. Statistical analysis was 
performed using one-tailed ANOVA. 
 
Antibodies. Murine anti-canine PD-1 and PD-L1 monoclonal antibodies, described recently
63,132
, 
were used for flow cytometry and immunofluorescence staining. An isotype matched, irrelevant 
antibody was used at the same concentrations for each study (eBioscience, San Diego, CA). 
Mouse mAbs were detected using a donkey anti-mouse secondary, conjugated to Alexa Fluor 
488 (Jackson ImmunoResearch, West Grove, PA). Mouse anti-canine CD21 (clone CA2.1D6), 
rat anti-canine CD5 (clone YKIX322.3), rat anti-canine CD8 (clone YCATE55.9), and rat anti-
canine CD4 (clone YKIX302.9) were obtained from Bio-Rad Laboratories (Hercules, CA) and 
used to identify lymphocyte populations. 
  
Flow cytometry. Fine needle aspirate samples for immunostaining were incubated with 
ammonium-chloride-potassium (ACK) lysis buffer (0.5% Phenol Red solution, 8% NH4Cl, 1% 
KHCO3, 0.037% Na2EDTA in distilled water) to lyse red blood cells and next washed with 
fluorescence-activated cell sorting (FACS) buffer (1% BSA in PBS with 0.05% sodium azide) 
before single cells in suspension were added to a 96 well round bottom plate (Falcon, Durham, 
NC) for immunostaining. Lymphoma cell lines were harvested and washed with PBS prior to 
plating and immunostaining. Addition of 10% normal dog serum (Jackson ImmunoResearch) 
was used with primary antibodies to minimize non-specific binding, and the samples were 
immunostained with antibodies diluted in FACS buffer. To exclude dead cells from analysis, 7-
AAD viability dye (eBioscience) was added prior to analysis, and 7-AAD
+
 cells were not 
analyzed. Cells were analyzed for fluorescence expression using a Beckman Coulter Gallios flow 
cytometer (Brea, CA). Data were analyzed using FlowJo Software (Ashland, OR). 
39	
Generation of chemotherapy-resistant canine cell lines. To create chemotherapy-resistant cell 
lines, we used a combination of doxorubicin, vincristine, and dexamethasone (all from Sigma-
Aldrich, St. Louis, MO) at 4 times the IC50 for each drug, as determined by in vitro assays (data 
not shown, 4 times the IC50s are as follows: CLBL1 cells: 845 ng/ml Dexamethasone, 3 ng/ml 
vincristine, and 80 ug/ml dexamethasone and Oswald cells: 30 ng/ml doxorubicin, 125 ng/ml 
vincristine, and 80 ug/ml dexamethasone). The cells were passaged and treated with a fresh dose 
of chemo-selection drugs every 3 days for 2 months. Cell death was measured by flow 
cytometric staining for 7-AAD and Annexin V (eBiosciences, San Diego, CA), and a minimum 
of 80% cell death was achieved after the first chemo-selection treatment (Figure 3.2). The 
chemo-selected cells were maintained in drugs until the resistant population expanded, at which 
point they were used for flow cytometric analysis of checkpoint molecule expression. 
 
Figure 3.2. Untreated (left) and chemo-resistant canine lymphoma cell lines (right) were stained 
for 7-AAD and Annexin V to measure cell death after 1 treatment of chemotherapy 
(Doxorubicin, Vincristine, and Dexamethasone at 4 times the IC50 for each drug). Shown is a 
representative flow cytometry plot of CLBL1 cells. 
 
Statistical analysis. Statistical comparisons between those data sets with two sample groups were 
done using non-parametric t-tests (Mann-Whitney test). Comparisons between 3 or more groups 
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were done using ANOVA, followed by Tukey multiple means post-test. Analyses were done 




PD-1 and PD-L1 expression by normal and malignant lymphocytes. Using flow cytometry, 
malignant canine lymphocytes in blood and lymph nodes by can be distinguished from normal 
lymphocytes, neutrophils, and monocytes by their larger size (high forward scatter) and medium 
granularity (medium side scatter)
155
. We therefore used these criteria for lymph node aspirate 
cells to distinguish malignant lymphocytes from tumor-infiltrating T cells and B cells. Live 
lymphocytes were identified by negative staining for 7-AAD and classified based on their 
expression of CD5 or CD21 prior to assessing the percentage of PD-1 and PD-L1 positive 




 T cells, based on 
positive staining for these markers. 
Comparison of PD-1 expression by malignant B cells in dogs with BCL and normal B 
cells from lymph nodes of healthy dogs showed no significant difference in expression, though 
malignant B cells from several dogs with BCL did express detectable PD-1 (Figure 3.3B). In 
dogs with TCL, we observed that malignant T cells from 6 dogs with CD4
+
 TCL were largely 
negative for expression of PD-1, whereas 50% of normal T cells expressed PD-1 (Figure 3.3C). 
PD-L1 expression by malignant lymphocytes was also evaluated in dogs with BCL and 
TCL (Figure 3.4A). The percentage of malignant B cells that were PD-L1
+
 (mean = 20%) was 




Figure 3.3 PD-1 expression by malignant B cells and T cells from dogs with BCL and TCL, respectively. Fine needle aspirates 
were obtained from lymph nodes of normal dogs and from lymph nodes of dogs with lymphoma (BCL or TCL) for flow cytometric 
analysis. The cells were stained for CD21 and CD5 to distinguish between B and T cells, and positive staining for PD-1 was 
determined with respect to cells stained with an irrelevant isotype antibody. The data were analyzed using FlowJo Software and the 
gating strategy is shown in (A) where PD-1 gating is based on isotype-stained malignant CD5
+
 lymphocytes. Data shown represents 
(B) malignant CD21
+
 B cells from dogs with BCL, while the plots in (C) represent malignant CD5
+
 T cells from dogs with TCL, both 
compared to corresponding normal B and T cells from lymph nodes of healthy dogs. Data are presented as mean ± SEM of the 
percentage of marker expression. Statistical analysis was performed using non-parametric t-test.
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Figure 3.4 Expression of PD-L1 by malignant cells from dogs with BCL and TCL. 
Fine needle aspirates were obtained from lymph nodes of normal dogs and from dogs with BCL or TCL for flow cytometric analysis. 
The cells were stained for CD21 and CD5 to identify B and T cells as shown in Figure 1, and positive staining for PD-L1 was 
determined with respect to cells stained with an irrelevant isotype antibody (A). The data were analyzed using FlowJo Software and 
data shown is (B) CD21
+
 tumor cells from lymph nodes of dogs with BCL and (C) CD5
+
 tumor cells from dogs with TCL compared 
to corresponding B and T cells from lymph nodes of normal dogs. Data are presented as mean ± SEM of the percentage of marker 
expression. Statistical analysis was performed using non-parametric t-test and statistically significant differences were denoted as ** = 
p < 0.005.
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(Figure 3.4B). In contrast, in animals with TCL, PD-L1 expression by both malignant CD5
+
 T 
cells and normal CD5
+
 T cells was either negative or very low, and the levels of expression were 
not statistically different between malignant and healthy cells (Figure 3.4C). These analyses 
revealed therefore that malignant B-lymphocytes primarily upregulated expression of PD-L1, 
and not PD-1. 
 
PD-1 and PD-L1 expression by tumor-infiltrating lymphocytes. Checkpoint molecule expression 
by tumor-infiltrating lymphocytes (T cells from BCL and B cells from TCL) was evaluated next, 
and levels of expression were compared to those on T cells and B cells in normal lymph nodes. 




 T cells in lymph nodes of 17 healthy dogs 
with 34 dogs with treatment-naïve BCL revealed significantly upregulated expression of PD-1 by 
T cells infiltrating lymph nodes in animals with BCL, compared to expression by PD-1 by T 
cells in normal lymph nodes (Figures 3.5A and 3.5B). In addition, we found that CD5
+
 T cells 
infiltrating BCL lymph nodes also expressed PD-L1, whereas T cells from healthy lymph nodes 
were PD-L1 negative (Figure 3.5C). This finding has been reported in human tumors, but to our 
knowledge, this is the first time this has been shown in dogs
156,157
.We also found increased PD-1 
and PD-L1 expression by B cells infiltrating lymph nodes in animals with TCL, compared to 
expression by normal B cells (Figure 3.5D and 3.5E). No correlation was found between tumor 
cell PD-L1 expression and tumor-infiltrating lymphocyte PD-L1 expression (data not shown). 
 
Effect of chemotherapy on PD-1 and PD-L1 expression by malignant lymphoma. Previous 
studies have suggested that chemotherapy may select for cells with upregulated checkpoint 
molecule expression, or may actually induce upregulated expression directly
158,159
. To address 
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whether the same thing occurs in canine lymphoma cells, CLBL1 (canine BCL) and Oswald 
(canine TCL) cells were treated with high-dose chemotherapy to generate chemotherapy resistant 
cell lines. We found that chemotherapy resistant cells (both CLBL1 and Oswald) exhibited 
significantly upregulated expression of both PD-1 (Figure 3.6A and 3.6B) and PD-L1 (Figure 
3.6C and 3.6D) compared to non-selected tumor cells. These findings indicated that 
 
Figure 3.5 PD-1 and PD-L1 expression by tumor-infiltrating lymphocytes in dogs with BCL 
and TCL. Flow cytometric analysis of tumor-infiltrating lymphocyte expression of PD-1 and 
PD-L1 was conducted using the same fine needle aspirates obtained from lymph nodes of normal 
dogs and from dogs with BCL and TCL used in the prior studies. The cells were stained for 
CD21 and CD5 to distinguish between B and T cells, and T cells were further identified by 
staining for CD4 and CD8. Positive staining for PD-1 and PD-L1 was determined with respect to 
cells stained with an irrelevant isotype antibody and the data were analyzed using FlowJo 
Software. Data shown is (A) PD-1 expression by CD4
+
 T cells, (B) PD-1 expression by CD8
+
 T 
cells and (C) PD-L1 expression by CD5
+
 T cells all from dogs with BCL, compared to 
corresponding cells from lymph nodes of normal dogs. In (D) is depicted PD-1 expression by 
CD21
+
 B cells and in (E) is expression of PD-L1 on CD21
+
 B cells from dogs with TCL. Data 
are presented as mean ± SEM of the percentage of marker expression. Statistical analysis was 
performed using non-parametric t-test and statistically significant differences were denoted as * 
= p < 0.05 and ** = p < 0.005. 
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chemotherapy resistance is associated with upregulation of checkpoint molecule expression. 
However, these studies did not determine whether selection induced upregulated checkpoint 
molecule expression, or whether high-dose chemotherapy was able to select for and expand a 
small subpopulation of cells that already expressed high levels of PD-1 and PD-L1. Interestingly, 
the BCL cell line showed only a slight increase in PD-L1 expression whereas the TCL cells 
showed both a PD-L1
+
 and a PD-L1
-
 population. These differences point to possible variations in 
mechanisms for upregulation of PD-L1 expression by canine lymphoma cells, i.e. induction of 
PD-L1 expression (BCL) versus selection of a subpopulation (TCL).  
 
 
Figure 3.6 Effect of chemotherapy selection on PD-1 and PD-L1 expression by lymphoma 
cell lines. The canine B cell lymphoma cell line CLBL1 and the T cell lymphoma cell line 
Oswald were treated with 4-times the IC50 dose of doxorubicin, vincristine, and dexamethasone 
for 2 months to select for chemotherapy-resistant cells. Untreated and chemotherapy-resistant 
cells were immunostained for expression of PD-1 and PD-L1, and positive staining was 
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determined with respect to irrelevant isotype antibody staining. PD-1 geometric MFI is depicted 
as histograms for CLBL1 cells (A) and Oswald cells (B), and histograms for PD-L1 are shown 
for CLBL1 cells in (C) and for Oswald cells in (D). Gray = isotype stain, blue = untreated cells, 
and red = chemotherapy-resistant line. These experiments were conducted with 3 separately 
selected chemo-resistant cell lines, with similar results each time. 
 
Comparison of PD-1 and PD-L1 expression by untreated versus relapsed lymphoma. The 
preceding in vitro studies indicated that malignant B cells and T cells exhibited higher levels of 
PD-1 and PD-L1 expression following exposure to cytotoxic chemotherapy. To determine 
whether a similar response occurred in vivo, PD-1 and PD-L1 expression by malignant B cells 
from dogs with treatment-naïve BCL was compared to expression by dogs with BCL following 
their first relapse after cytotoxic chemotherapy. Surprisingly, no difference in PD-1 or PD-L1 
expression was observed, though the number of relapsed animals evaluated (eight dogs) was 
relatively low (Figure 3.7A and 3.7B). Thus, at present it remains unclear to what degree 
chemotherapy exposure alters PD-1 and PD-L1 expression by lymphoma cells in dogs with BCL.  
 
Figure 3.7 PD-1 and PD-L1 expression by tumor cells from dogs with relapsed BCL, 
compared to expression by tumor cells from untreated BCL. Fine needle aspirates were 
obtained from lymph nodes of untreated dogs and from dogs with relapsed BCL for flow 
cytometric analysis. The tumor cells were stained for CD21 and CD5 to distinguish between 
malignant B and T cells, and positive staining for PD-1 and PD-L1 was determined with respect 
to cells stained with an irrelevant isotype antibody. PD-1 expression by malignant CD21
+
 B cells 
is shown in (A) and PD-L1 by malignant CD21
+
 B cells is shown in (B). The data were analyzed 
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using FlowJo Software and presented as mean ± SEM of the percentage of marker expression on 
lymphocytes. Statistical analysis was performed using two-tailed ANOVA, followed by Tukey’s 
multiple means comparison.   
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Two dogs in this study (both with BCL) had pre-treatment and post-relapse samples 
available for comparison. In one animal, there was no difference in pre-and post-relapse PD-L1 
expression by malignant B cells, whereas in the other dog, PD-L1 expression by malignant B 
cells was higher in samples obtained from the relapsed tumors (data not shown). We found that 
the dog with increased PD-L1 expression by malignant B cells post-relapse received standard 
CHOP induction therapy whereas the dog with no change in PD-L1 expression received 
doxorubicin induction chemotherapy. Thus, in these very preliminary studies, there was 
agreement with the in vitro finding of upregulated PD-L1 expression by CHOP chemotherapy. 
These results indicate that additional analysis of paired pre- and post-relapse samples, followed 
for longer periods of time, and treated with different chemotherapy protocols is warranted. 
 
Discussion. 




) in human 
patients with diffuse large B-cell, follicular, and Hodgkin lymphoma has generated considerable 
enthusiasm based on overall response rates of up to 50%, with durable responses in up to 90% of 
responding patients
160-162
. Furthermore, gene expression profiles of several subtypes of canine 
and human B cell lymphomas have even been found to be similar, possibly with the same 
mutational drivers
163
. These findings have, not surprisingly, stimulated considerable interest in 
similar immunotherapeutic approaches for treatment of lymphoma in dogs. 
Two previous reports have evaluated PD-1 and PD-L1 expression in dogs with 
lymphoma
52,53
. One report indicated that none of 5 canine BCL lymphomas biopsies evaluated 
revealed PD-L1 expression, as assessed by immunohistochemistry
52
. In contrast, a second report 




. An explanation for these very discordant results is not immediately 
apparent, though differences in methodology (eg, different PD-L1 antibodies were utilized) is 
one likely explanation. Certainly our results are much more in agreement with those of Shosu et 
al.
53
, and suggest that PD-L1 expression is highly upregulated in all or nearly all dogs with BCL. 
Moreover, we recently found that PD-L1 expression could be detected on all of 14 canine tumor 
cell lines evaluated, and that PD-L1 expression was strongly upregulated by exposure to 
cytokines such as IFN-g
63
.  
We and others have reported that PD-1 blocking antibodies can enhance activation of 
canine T cells in vitro
132,133
. We also found that PD-1 expression was significantly upregulated 
by T cells from dogs with cancer compared to healthy age-matched animals
132
. Therefore, there 
is strong rationale for concluding that PD-1 and PD-L1 targeted immunotherapy might be 
effective in treatment of canine lymphoma. Indeed, a recent report describes the first 
administration of fully canine PD-L1 antibody immunotherapy in dogs (though not in dogs with 
BCL), with some evidence of clinical activity
133
.  
In our studies, we did not observe increased PD-1 expression by malignant cells in dogs 
with BCL or TCL. However, expression of PD-L1 by malignant B cells was significantly 
increased relative to expression by normal B cells from healthy dog lymph nodes. In addition, 
expression of both PD-1 and PD-L1 was increased on tumor infiltrating T cells in dogs with BCL 
and on tumor infiltrating B cells in dogs with TCL. Studies of human cancers have found 
somewhat paradoxically that increased PD-L1 expression by tumor infiltrating immune cells, 





We also evaluated the impact of chemotherapy treatment on expression of the PD-1 and 
PD-L1 by canine lymphoma cells, as previous studies have reported upregulated expression in 
human cancers following chemotherapy
158,159
. We found that continuous exposure to a partial 
high dose CHOP combination (doxorubicin, vincristine, and dexamethasone) resulted in 
significantly higher expression of both PD-1 and PD-L1 by canine BCL and TCL cell lines, 
especially by a TCL cell line. When tumors from 9 dogs with relapsed BCL were examined, 
expression of PD-1 and PD-L1 by malignant B cells were not significantly higher than on 
malignant B cells from treatment-naïve tumors. However, our in vitro data suggests that 
malignant T cells from CHOP-relapsed TCL patients would show more significantly upregulated 
immune checkpoint molecules compared to untreated dogs. It is also likely that the in vitro 
models of chemotherapy selection we used our studies do not fully recapitulate the events 
regulating PD-L1 expression in vivo following chemotherapy and development of relapse. The 
variability in PD-L1 expression observed in treatment-naïve samples from animals with BCL 
suggests that clinical trials to evaluate PD-1 or PD-L1 targeted immunotherapy in dogs with 
lymphoma should include a pre-treatment evaluation of PD-L1 expression levels for use as 
inclusion or exclusion criteria. 
In summary, PD-L1 expression was found to be significantly higher on malignant B cells 
in dogs with BCL, compared to normal B cells from lymph nodes. Numerous studies in humans 
and mice have found that increased PD-L1 expression by tumor cells correlates with a worse 
prognosis
38,39,46,164
. Of note, PD-L1 expression by non-Hodgkin lymphoma patients was reported 
to correlate with a worse prognosis
165
. Malignant T cells in animals with TCL did not, however, 
exhibit upregulated expression of either PD-1 or PD-L1. In tumor-infiltrating T cells in dogs 






cells, consistent with tumor-induced T cell exhaustion or immune suppression
36,166
. Upregulated 
expression of PD-1 was not observed on either malignant B cells or on malignant T cells. 
Interestingly, a population of dual-positive PD-1/PD-L1
+
 tumor infiltrating T cells was also 
observed in dogs with BCL, whereas similar dual-positive cells have not been observed in the 
peripheral blood of dogs with cancer
132
, or in the lymph nodes of healthy dogs. The significance 
of these dual expressing T cells is currently not known, but may suggest strong immune 
activation with concurrent checkpoint molecule expression upregulation. Correlations between 
checkpoint molecule expression by BCL and TCL and overall treatment outcomes, as well as the 
effects of chemotherapy selection and relapse, continues to be areas of strong clinical interest. 
The eventual approval of a canine PD-1 antibody for clinical use will undoubtedly drive new 
interest in checkpoint molecule expression and the predictive utility of examining these pathways 
in lymphoma and other canine tumors.  
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CHAPTER 4 
Regulation of PD-L1 Expression on Murine Tumor-associated Monocytes and 
Macrophages by Locally Produced TNF-a 
 
Summary. 
PD-L1 is an immune checkpoint protein that has emerged as a major signaling molecule 
involved with tumor escape from T cell immune responses. Studies have shown that intra-
tumoral expression of PD-L1 can inhibit antitumor immune responses. However, it has recently 
been shown that expression of PD-L1 on myeloid cells from the tumor is a stronger indicator of 
prognosis than tumor cell PD-L1 expression. Therefore, it is important to understand the factors 
that govern the regulation of PD-L1 expression on tumor-infiltrating myeloid cells. We found 
that immature bone marrow monocytes in tumor-bearing mice had low levels of PD-L1 
expression, while higher levels of expression were observed on monocytes in circulation. In 
contrast, macrophages found in tumor tissues expressed much higher levels of PD-L1 than 
circulating monocytes, implying upregulation by the tumor microenvironment. We demonstrated 
that tumor-conditioned media strongly induced increased PD-L1 expression by bone marrow-
derived monocytes and TNF-α to be a cytokine that causes an upregulation of PD-L1 expression 
by the monocytes. Furthermore, we found production of TNF-α by the monocytes themselves to 
be a TLR2-dependent response to versican secreted by tumor cells. Thus, PD-L1 expression by 






The tumor microenvironment (TME) plays a critical role in the ability of tumor cells to 
successfully establish themselves in tissues
167
. Several cell types comprise the TME stroma, 
including fibroblasts, endothelial cells, macrophages, neutrophils, and B and T cells
168
. 
Interactions between stromal cells and tumor cells support tumor growth and metastasis
169
. 
Macrophages are one of the key cellular constituents of the TME, and serve to suppress T cell 
immune responses, stimulate tumor angiogenesis, promote tumor metastasis, and generate 
additional genomic instability
170,171
. The recruitment of monocytes to tumors in response to 
tumor-derived chemokines, in particular CCL2, is associated with aggressive tumor growth and 
metastasis
172,173
. Immature monocytes are also precursors of tumor-associated macrophages 
(TAM), which have an immune-suppressive phenotype
174
.  
How TAM suppress tumor immunity is currently an area of intense research interest, and 
a number of investigations have focused on checkpoint molecules expressed by TAM as a means 
of negative regulation of T cell function
99,102
. Studies have reported that PD-L1-expressing 
macrophages were more abundant than PD-L1 expressing tumor cells in tumor biopsy specimens 
from patients with melanoma, renal cell carcinoma, non-small cell lung, head and neck 
carcinoma, and colorectal tumors
99,102
. One recent study reported that hypoxic conditions 
selectively upregulated PD-L1 expression by myeloid-derived suppressor cells and macrophages 
through HIF-1α
49
. However, little more is known about how PD-L1 expression by macrophages 
is regulated, and specifically how the tumor microenvironment influences PD-L1 expression by 
TAM.  
In the present study, we addressed the questions of how PD-L1 expression changed over 
time during macrophage differentiation from monocytes to mature macrophages, and which 
54	
cytokines produced in the local tumor microenvironment were responsible for maintaining high 
levels of PD-L1 expression by TAM. Therefore, we utilized in vitro assays to identify cytokines 
that regulate myeloid cell PD-L1 expression as well as the source of these cytokines. We 
hypothesized that PD-L1 expression by macrophages is primarily regulated by IFN-γ, similar to 
the regulation of PD-L1 expression by tumor cells in humans, mice, and dogs
61-64
. We also used 
monocytes and macrophages from genetic knockout mice to identify a novel signaling loop that 
regulates myeloid cell PD-L1 expression in the tumor environment.  
 
Materials & Methods. 
Mice and tumor models. Wild-type (WT), IFN-γ
-/-













/J) bred on the C57Bl/6 background were acquired from Jackson Laboratories 
(Sacramento, CA), as were BALB/c mice. C57Bl/6 were inoculated s.c in the flank with 1 x 10
6
 
B16.F10 melanoma cells in 100 ul PBS (Gibco, Grand Island, NY). BALB/c mice were 
inoculated similarly with 4T1 mammary carcinoma cells. According to the study IACUC 
protocols, the mice were humanely euthanized when the tumor diameters reached 10 mm or less. 
Tumor area was determined the day the mice were euthanized, with tumor area calculated as 
length x width in mm. 
  
Murine cell lines. B16.F10 melanoma cells and 4T1 mammary carcinoma cells were obtained 
from ATCC (Manassas, VA).  These cell lines were screened by PCR to ascertain that they were 
of murine origin
134
.   
 
55	
Tissue preparation for flow cytometry. Mice were euthanized before spleens and tumor tissues 
were harvested. Tumor tissues were minced with fine scissors, then digested with collagenase 
(Sigma Aldrich, St. Louis, MO) for 30 minutes at 37°C and filtered to obtain a single cell 
suspension. Spleen cells were collected by forcing cells through 70 micron filters with cell 
culture medium. Tissue and blood samples were lysed with ammonium-chloride-potassium 
(ACK) lysis buffer (0.5% Phenol Red solution, 150mM ammonium chloride, 10 mM potassium 
bicarbonate, 0.1 mM disodium salt dihydrate) and the remaining cells were washed with cell 
culture medium in preparation for flow cytometric staining.  
 
Bone marrow collection and monocyte enrichment. Bone marrow was collected from tibias and 
femurs by forcing cells out of the marrow cavity, using tissue culture medium and a 25# needle. 
The bone marrow cells were then lysed with ACK lysis buffer and washed with medium before 
plating in 24-well polystyrene cell culture plates (Falcon, Durham, NC) for the selection of 
adherent monocytes. Adherent bone marrow-derived monocytes were then harvested by 
pipetting with ice-cold 2mM EDTA in PBS (Gibco).  
 
Generation of conditioned medium. Tumor cells were cultured in the same cell culture medium 
described previously. To generate tumor-conditioned medium (CM), tumor cells were seeded 
into 24-well plates at 75,000 cells/ml and CM was collected 24 hours later. The CM was then 
centrifuged to remove any remaining cells. 
 
Co-culture studies and conditioned medium effects on monocyte PD-L1 expression. Bone 
marrow-derived monocytes were selected by adherence as described above and washed with 
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PBS. Tumor cells at 50,000 cells/ml or tumor CM at 50% were added to cultures of bone 
marrow-derived monocytes. After 18 hours of culture, monocytes were harvested as described 
above and processed for flow cytometry. These culture conditions routinely yielded monocyte 
cultures that were at least 80-90% pure. 
 
Flow cytometry. Cells prepared from tumor and liver tissues, as well as bone marrow-derived 
monocytes, blood monocytes, and TAM were obtained as described above and placed in FACS 
buffer for immunostaining. Nonspecific antibody binding was blocked by addition of normal 
mouse serum and 0.01% Fc-specific antiserum (CD16/32, clone 93, eBioscience, San Diego, 
CA). 
Cells were immunostained with the following antibodies: CD45 Pacific Orange (Clone 
30-F11) from Invitrogen (Grand Island, NY) to identify hematopoietic cells, and with PD-L1 PE 
(clone MIH5), CD11b Pacific blue (clone M1/70), F4-80 APC (clone Cl:A3-1), Ly6C biotin 
(AL-21), Ly6G Alexa 488 (clone 1A8), CCR2 APC (clone 475301), and CD11c FITC (clone 
N418). Cells were also stained with appropriately matched isotype antibodies to assure 
specificity of immunostaining. All antibodies were purchased from eBioscience unless otherwise 
noted.  
Prior to analysis, 7-AAD viability dye (eBioscience) was added to flow samples to 
exclude dead cells. Cells were analyzed using a Beckman Coulter Gallios flow cytometer (Brea, 
CA) and FlowJo Software (Ashland, OR).   
In other experiments, intracellular cytokine expression was quantitated. To measure 
intracellular expression of TNF-α, the cells were initially stained for surface markers before 
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fixation with paraformaldehyde (PFA), and permeabilization with 0.25% saponin. Cells were 
then washed and immunostained with an TNF-α PE antibody (clone MP6-XT22, eBioscience). 
Cytokines for PD-L1 upregulation by monocytes and macrophages. The following recombinant 
murine cytokines were purchased from Peprotech (Rocky Hill, NJ): TNF-α, TGF-β, IL-10, 
MCP-1, IFN-γ, GM-CSF, and IL-3. Each cytokine was used at 10 ng/ml, according to the 
manufacturer’s suggested working concentrations and based on titration studies done in our 
laboratory (data not shown). Bone marrow-derived monocytes were stimulated with these 
cytokines for 24 hours prior to analysis of PD-L1 expression by flow cytometry.  
 
Neutralizing antibodies. A TNF-α neutralizing antibody (clone NF-7, Abcam, Cambridge, UK) 
was used at 5 ug/ml in tumor CM prior to treatment of monocytes with tumor CM. A rabbit 
polyclonal versican antibody (Santa Cruz, Santa Cruz, CA) was used at 200 ug/ml in tumor CM 
for 4 hours at 4C. This was followed by incubation of CM and anti-versican antibodies with 
protein A sepharose beads (Abcam) overnight according to manufacturer’s protocol for 
immunoprecipitation of antibodies. The beads were removed from the CM by centrifugation 
prior to CM being added to monocyte cultures. 
 
ELISA. Cell culture supernatants were collected and centrifuged for the removal of cells.  
Cytokines were measured using specific ELISA kits for murine IFN-γ and TNF-α (R&D 
Systems, Minneapolis, MN), and assays were performed according to manufacturer directions. 
 
Tissue immunofluorescence staining and imaging. Tumor tissues were harvested and fixed in 
periodate-lysine-paraformaldehyde (PLP) for 24 hours before transferring to a 30% glucose 
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solution for another 24 hours, all at 4C. Afterwards, tissues were embedded in OCT (Optimal 
Cutting Temperature compound), frozen at -80C, and cryosectioned to a thickness of 5 microns. 
The tissues were mounted on glass slides and blocked with 5% donkey serum for 30 minutes 
prior to staining.  
For analysis of PD-L1 expression, we used an unlabeled antibody (clone 10F.9G2, 
BioXcell, West Lebanon, NH). For analysis of intracellular TNF-α expression, a directly 
conjugated antibody (clone MP6-XT22) and a matched irrelevant isotype control antibody from 
eBioscience were used. For detection of macrophages, an unconjugated F4-80 antibody (clone 
BM8) was used. 
Antibodies for PD-L1 and F4-80 and their matched isotype controls were used overnight 
at 4C, followed by a donkey anti-rat antibody (Jackson Immunoresearch, West Grove, PA) for 
30 minute to detect primary antibody binding. For dual staining, antibodies for intracellular 
cytokines were diluted in 0.25% Saponin diluted in PBST overnight at 4C. Finally, the tissues 
were stained with DAPI to identify nucleated cells and coverslipped with Prolong Diamond 
mounting media (LifeTech, Carlsbad, CA) before imaging. Controls included immunostaining 
with appropriate concentrations of irrelevant isotype-matched antibodies. Figures were then 
compiled using Adobe Photoshop. 
 
Statistical analysis. Statistical comparisons between those data sets with two treatment groups 
were done using non-parametric t-tests (Mann-Whitney test). Comparisons between 3 or more 
groups were done using ANOVA, followed by Dunnet’s or Tukey multiple means post-test. 
Analyses were done using Prism6 software (GraphPad, La Jolla, CA). For all analyses, statistical 
significance was determined for p < 0.05. 
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Results. 
Role of endogenous IFN-γ regulation of PD-L1 expression by monocytes and tumor 
macrophages. Our studies and those of others have found that IFN-γ can significantly upregulate 
PD-L1 expression by both tumor cells and macrophages
62,175
. Using bone marrow-derived 
macrophages and monocytes, we confirmed that exposure to IFN-γ resulted in significant 
upregulation of PD-L1 expression by monocytes, as well as by tumor cells (data not shown). 
Moreover, a previous investigation evaluated the role of endogenous cytokines in regulating PD-
L1 expression by tumor cells and myeloid cells in vivo, and concluded that IFN-γ produced by 
inflammatory cells stimulated tumor cells to increase their PD-L1 expression
176
. However, this 
previous study did not conclusively assess the role of IFN-γ in regulating PD-L1 expression by 
tumor-associated macrophages.  
Therefore, we used mice lacking expression of IFN-γ to address more fully the role of 
endogenous IFN-γ in regulating both tumor and TAM PD-L1 expression in vivo. B16.F10 
tumors were grown in both WT and IFN-γ
-/-
 mice (n = 5 per group), and tumor tissues were 
processed for flow cytometry for assessment of PD-L1 expression by tumor cells and TAM. We 
found that CD45
-
 tumor cells in IFN-γ
-/-
 mice expressed significantly less PD-L1 than tumor 
cells obtained from WT animals (Figure 4.1A). However, macrophages in tumor tissues from 
WT and IFN-γ
-/-
 mice expressed similar levels of PD-L1, based on both MFI and % positive 
analysis (Figure 4.1B). While these data confirm previous studies with respect to the essential 
role for IFN-γ in regulating tumor cell PD-L1 expression, the new findings suggested that PD-L1 
expression by TAM was regulated in an IFN-γ-independent fashion. 
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Effect of monocyte maturation into macrophages on PD-L1 expression. We next sought to 
determine the role of monocyte differentiation into tissue macrophages on regulation of PD-L1 
expression. For example, it is possible that macrophages in tumor tissues express higher levels of 
PD-L1 simply as a result of maturation-related changes. Therefore, we used flow cytometry to 
examine the level of PD-L1 expression by immature monocytes in bone marrow, circulating 
monocytes, and macrophages in normal and tumor tissues. 
We found that indeed, the level of PD-L1 expression by monocytes increased as the cells 
age, with the lowest levels of expression in the bone marrow and the highest levels of expression 
observed in spleen and tumor tissues (Figure 4.1C and 4.1D). PD-L1 expression was measured 


















). Importantly, in tumor tissues the more recently 
emigrated inflammatory monocytes (as assessed by higher levels of expression of CCR2
172,173
) 
expressed higher levels of PD-L1 than resident macrophages, suggesting that the newly arrived 
monocytes further upregulated their PD-L1 expression once they reached tumor tissues. 
 
In vitro regulation of monocyte PD-L1 expression by tumor-conditioned medium. These findings 
suggested that factors produced locally in tumor tissues were responsible for upregulation of PD-
L1 expression. To address this question, we developed a co-culture system in which immature 
bone marrow-derived monocytes were co-cultured with tumor cell conditioned medium (CM). 
We found that culture of monocytes with tumor CM resulted in rapid and significant 
upregulation of PD-L1 expression (Figure 4.2A). For example, exposure to as little as 25% CM 
triggered significant PD-L1 upregulation, and that the effect occurred within 18h (data  
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Figure 4.1 PD-L1 expression by tumor cells, monocytes, and macrophages in vivo. B16 
tumors cells were established s.c. in WT and IFN-γ
-/-
 mice (n = 3-5 animals per group), as noted 
in Methods. Single cell suspensions were prepared from excised tumor tissues and flow 
cytometry was used to compare PD-L1 expression by CD45
-







) in (B) obtained from the two groups of mice. 
The mean percentage of PD-L1
+
 cells present in tumor tissues from WT and IFN-γ
-/-
 are depicted 
















) were harvested from the spleens of healthy mice and from 
tumors of mice with established s.c. B16 tumors (n = 4-5 mice per group) and PD-L1 expression 
was quantitated by flow cytometry.  The level of expression of PD-L1 on the cells is shown as 
histograms of geometric MFI in (D) where gray filled = isotype stain, dotted line = cells from 
62	
healthy mice, and solid line = cells from tumor-bearing mice from bone marrow, blood, and 
tissues. The mean percentages of PD-L1
+
 cells in healthy mice and mice with tumors were 
compared statistically using a non-parametric t-test, and mean percentages of PD-L1
+
 cells in 
different tissues from healthy and tumor-bearing mice were compared using two-tailed ANOVA, 
with Tukey post-test.  Groups means with statistically significant differences were denoted as * = 
p < 0.05, *** = p < 0.0005, and **** = p < 0.0001. Similar results were obtained in 2 additional, 
independent experiments. 
 
not shown). It was also observed that CM from certain tumor cell lines led to greater 
upregulation of PD-L1 expression by monocytes than CM from others (Figure 4.2A).  
 
Cytokine production in tumor and monocyte co-cultures. Several secreted cytokines or growth 
factors were considered candidates for the secreted PD-L1 upregulation, based on previous 
work
65,177-180
, including GM-CSF, MCP-1, IL-10, IL-3, TGF-β, or TNF-α. To help identify the 
relevant factors, we first screened recombinant cytokines to identify those that most strongly 
upregulated PD-L1 expression in the bone marrow monocyte system (Figure 4.2B). Using this 
screen, we identified IFN-γ and TNF-α as potential candidate cytokines (Figure 4.2C). TNF-α is 




 inflammatory monocytes are 
especially responsive to this cytokine (Figure 4.3A)
182,183
. 
To directly address the role of each cytokine, neutralization studies were done. Here we 
found that neutralization of GM-CSF and IL-10 did not result in significant reduction in PD-L1 
upregulation in response to tumor CM (data not shown). However, when tumor CM was treated 
with TNF-α neutralizing antibody, the upregulation of PD-L1 was significantly abrogated 
(Figure 4.3B). Furthermore, CCR2
+
 monocytes showed significantly lower expression of PD-L1 
in comparison to CCR2
-
 monocytes, supporting the previous experiment using exogenous 
recombinant TNF-α in that CCR2
+




Figure 4.2 Effects of tumor cells, tumor CM, and cytokines on monocyte PD-L1 expression.  
(A) B16 and 4T1 tumor cells were grown as monolayers, then co-cultured with bone marrow-
derived monocytes for 24h, as described in Methods. In other studies, bone marrow-derived 
monocytes were cultured with CM from tumor cells. The effects of co-culture with live tumor 
cells or with tumor CM on monocyte PD-L1 expression was determined by flow cytometry. (B) 
Bone marrow-derived monocytes were prepared as described in Methods and incubated with the 
following murine recombinant cytokines (TNF-α, TGF-β, IL-10, MCP-1, IFN-γ, GM-CSF, and 
IL-3) at a concentration of 10 ng/ml. After overnight culture, the monocytes were collected and 
immunostained for flow cytometric analysis of PD-L1 expression. (C) Histograms of monocyte 
PD-L1 expression following exposure to TNF-α or IFN-γ. The percentage of PD-L1
+
 cells was 
compared between monocytes cultured in medium only and monocytes exposed to tumor cells, 
tumor CM, or cytokines using one-tailed ANOVA, followed by Dunnet’s multiple means 
comparison.  Statistically significant differences were denoted as ** = p < 0.005, *** = p < 




by TNF-α (Figure 4.3B). These findings suggested therefore that TNF-α might be the more 
important cytokine in the tumor environment for upregulation of PD-L1 expression.  
 
 
Figure 4.3 Neutralization of TNF-α significantly blocks upregulation of monocyte PD-L1 
expression by tumors. (A) Bone marrow-derived monocytes were treated with increasing 
concentrations of recombinant TNF-α (0.1-50 ng/ml), and PD-L1 expression was compared 

















). (B) Conditioned medium from 4T1 cells was treated 
with a TNF-α neutralizing antibody (or isotype control antibody), then incubated with triplicate 
wells of bone marrow-derived monocytes for 24h. Effects of tumor CM on monocyte PD-L1 

















). Similar results were obtained in 3 
additional independent experiments. Statistical comparison of TNF-α concentrations was done 
by two-tailed ANOVA, followed by Tukey’s multiple means comparison. Statistically significant 
differences were denoted as * = p < 0.05 and ** = p < 0.005.  
 
The concentrations of TNF-α in tumor and monocyte CM were then measured by ELISA, 
and these concentrations correlated with the degree of observed PD-L1 upregulation by co-
cultured monocytes (Figure 4.4A). First, we found that CM from any of the cells alone 
contained undetectable concentrations of TNF-α, which indicates that tumor cells were not the 
source of TNF-α production. Therefore, we examined TNF-α concentrations in the CM of 
monocytes that had been co-cultured with tumor CM. We observed high concentrations of TNF-
α in the monocyte CM following incubation with tumor CM, suggesting production by the 
monocytes. We also used intracellular staining and found TNF-α production by monocytes 
cultured with tumor CM (Figure 4.4B). In contrast, IFN-γ concentrations in the same CM were 
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undetectable (data not shown). Thus, it appeared that tumor cells in culture spontaneously 
secreted a factor that stimulated monocytes to produce TNF-α, which in turn led to greater 
upregulation of PD-L1 expression by the monocytes themselves.  
 
Figure 4.4 Tumor cells and tumor-secreted factors stimulate TNF-α production by 
monocytes. (A) Bone marrow monocytes were cultured overnight with B16 cells or 4T1 cells, or 
with tumor CM derived from these cells. Medium from monocyte cultures was collected 24h 
after co-culture with live tumor cells or with tumor CM, and IFN-γ and TNF-α concentrations 
were determined by ELISA. (B) Bone marrow-derived monocytes were cultured overnight with 
tumor CM then incubated with Brefeldin A for 4h and immunostained for detection of 
intracellular TNF-α expression by flow cytometry. Appropriate isotype control antibodies were 
used to assess the specificity of TNF-α staining. Similar results were obtained in 3 additional 
independent experiments. Statistical comparison of TNF-α concentrations was done by one-
tailed ANOVA, with Dunnet’s post-test. Statistically significant differences were denoted as *** 
= p < 0.0005 and **** = p < 0.0001. 
 
Regulation of monocyte TNF-α production by tumor-secreted factors. Previous studies have 
described factors spontaneously secreted by tumor cells that led to TNF-α production by 
TAM
184,185
. These factors were also reported to stimulate macrophages to produce TNF-α in a 
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TLR2-dependent manner. Therefore, we first used TLR2
-/-
 bone marrow monocytes to elucidate 
the role of TLR2-dependent signaling in monocyte upregulation of TNF-α production, and 
ultimately PD-L1 upregulation. We found that monocytes unable to signal via the TLR2 pathway 
failed to secrete TNF-α and to upregulate PD-L1 (Figure 4.5A). Thus, this finding was 
consistent with a signaling pathway similar to that described previously for tumor-induced 
macrophage TNF-α production, through stimulation of TLR2 by extracellular matrix protein 
versican
184
. To this end, we found that removal of extracellular matrix protein versican from CM 
led to an abrogated upregulation of TNF-α production and PD-L1 expression compared to 
monocytes cultured with tumor CM alone (Figure 4.5B). These data suggest that versican is a 
primary mediator of TNF-α production and PD-L1 expression upregulation by monocytes. 
 
 
Figure 4.5 Versican secreted by tumor cells induces monocyte TNF-α production via TLR2 
signaling pathway. Triplicate wells of bone marrow monocytes generated from WT or TLR2
-/-
 
mice were cultured with tumor CM overnight. The monocytes were then detached and processed 
for detection of intracellular TNF-α expression and surface PD-L1 expression using flow 
cytometry in (A). In (B), versican was immunoprecipitated out of tumor CM using versican 
antibodies and protein A beads prior to culture with bone marrow-derived monocytes. The 
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monocytes were immunostained for surface PD-L1 expression and incubated with Brefeldin A 
for 4h and immunostained for detection of intracellular TNF-α expression by flow cytometry. 
Statistical comparison of TNF-α and PD-L1 expression was done by two-tailed ANOVA, with 
Tukey post-test. Statistically significant differences were denoted as * = p < 0.05, ** = p < 
0.005, and *** = p < 0.0005. This experiment was repeated once, with similar results. 
 
Cellular source of TNF-α production in tumor tissues and role of TNF-α in vivo. Finally, 
experiments were done to determine the in vivo source of TNF-α production within tumor 
tissues. Using tissues from subcutaneous B16 tumors, we found strong, constitutive expression 
of both TNF-α and PD-L1 throughout tumor tissues (Figure 4.6A). Co-localization studies 
revealed the source of TNF-α production was primarily F4/80
+
 macrophages, thus confirming in 
vivo the feedback loop described by our in vitro studies (Figure 4.6B). We also conducted 
studies using TNFR
-/-
 mice to assess the role of TNF-α in regulating tumor growth in the B16 
model. We found B16 tumors grown in TNFR
-/-
 mice were significantly smaller than those 
grown in WT mice (Figure 4.7). Furthermore, there were significantly decreased numbers of 
PD-L1
+
 tumor-associated macrophages and dendritic cells but not tumor cells from TNFR
-/-
 mice 
(Figure 4.6C), supporting the results observed with in vitro studies. 
 
Discussion. 
 Factors that regulate PD-L1 expression on TAM and monocytes have not been previously 
identified, which provided the impetus for the current study. In our investigations, we found that 
monocytes progressively upregulated PD-L1 expression as they matured and entered tumor 
tissues. In addition, we also identified a feed-forward loop regulating PD-L1 expression on 
TAM, wherein tumor-secreted versican triggered TNF-α secretion by macrophages. This in turn 
stimulated local upregulation of PD-L1 expression by the same macrophages. These findings 
suggest that PD-L1 expression by macrophages and monocytes in tumor tissues is regulated 
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Figure 4.6 In vivo TNF-a production within tumor tissues and effects on tumor-associated macrophage PD-L1 expression. (A) 
B16 tumors were collected from the s.c. tissues of mice, cryosectioned, and immunostained for detection of F4/80 (green) and PD-L1 
expression (red and counterstained with DAPI (blue). (B) Tumor tissues were immunostained for co-localization of F4/80 (green) and 
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TNF-α (red), and counterstained with DAPI (blue) for nuclear detection as noted in Methods. Depicted are representative images 
obtained from 6 separate tumors processed and immunostained for PD-L1, TNF-α, and F4/80. (C) Tumor tissues from WT and TNFR
-
/-













). Mean percentages of PD-L1
+
 cells were compared using non-




Figure 4.7 Effects of TNF-α on tumor size. B16 tumors were grown in WT and TNFR
-/-
 mice 
and measured when the mice were euthanized. Tumor area was calculated as length x width in 
mm. 
 
primarily by maturation and by locally produced TNF-α. Macrophage PD-L1 expression was 
largely independent of local IFN-γ production, in contrast to tumor cells, which were found to be 
much more dependent on IFN-γ for upregulated PD-L1 expression. Therefore, these results 
provide a clearer understanding of the regulation of PD-L1 in the TME. 
 Consistent with previous reports, we found that tumor cell PD-L1 expression was 
primarily regulated by endogenous production of IFN-γ
61,62
, inasmuch as PD-L1 expression was 
significantly reduced in IFN-γ
-/-
 mice. However, expression of PD-L1 by TAMs in IFN-γ
-/-
 mice 
was unchanged compared to WT animals. These findings suggested alternative, IFN-γ-
independent mechanisms for regulation of PD-L1 expression on TAM and monocytes.  
One mechanism regulating PD-L1 expression by macrophages identified in this study 
was cellular maturation. For example, we observed that the level of PD-L1 expression (both in 
terms of the total percentage of PD-L1
+
 cells and the overall level of PD-L1 expressed by each 
cell) underwent significant upregulation as cells matured from bone marrow monocytes, to 
circulating monocytes, to macrophages in tumor and spleen tissues. Thus, monocytes likely 
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become more effective at downregulating T cell responses as they mature and enter tissues, 
which is consistent with the normal immune homeostatic role of the PD-1/PD-L1 axis
21,22
. 
 Our investigations also revealed a previously unrecognized role for TNF-α in regulating 
PD-L1 expression by TAM. We found that TNF-α produced by monocytes themselves, in 
response to tumor-secreted versican, was the key cytokine responsible for upregulated PD-L1 
expression on monocytes. The tumor-secreted versican triggered TNF-α production in a TLR2-
dependent manner, consistent with the previously reported pro-inflammatory effects of tumor 
extracellular matrix proteins
184
. Versican is also involved in extracellular matrix formation 
during inflammatory reactions to provide a scaffold for the adhesion of recruited immune cells 
such as monocytes, and even enhances cellular adhesion to the scaffolds
56
. Furthermore, we 
determined that less mature monocytes (pro-inflammatory CCR2
+
 monocytes) were more 
responsive to TNF-α than non-inflammatory, CCR2
-
 monocytes. This finding suggests that 
within the TME, newly recruited inflammatory monocytes are likely to be a major source of high 
level PD-L1 myeloid cells, which would have the greatest negative impact on tumor-infiltrating 
T cells. These pro-inflammatory, PD-L1
hi
 monocytes are also the most likely to be recruited in 
response to T cell-generated inflammation and CCL2 production, serving to counter-balance T 
cell inflammatory stimuli with anti-inflammatory immune regulatory responses
172,173
.  
 Previous studies have reported that monocyte-derived IL-10 was an important stimulus 
for PD-L1 expression upregulation by human monocytes, and that TNF-α exerted only a 
marginal effect on PD-L1 expression
58
. In contrast, we found that IL-10 had little effect on 
monocyte PD-L1 expression, and that TNF-α was a very potent signal for PD-L1 upregulation. 
These differing findings may be explained by use of different monocyte populations (ie bone 
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marrow vs blood) obtained using different culture techniques. In addition, it is also possible that 
the murine and human monocytes respond differently to IL-10 and TNF-α. 
 In our studies, we found that tumor cells regulated monocyte PD-L1 expression via a 
contact-independent mechanism. TNF-α was produced by monocytes when cultured with tumor 
CM, and neutralization assays revealed that TNF-α was the principle cytokine responsible for 
this effect. We did not use mature macrophages for these assays because they have such high 
levels of PD-L1 expression that a treatment effect cannot be discerned (data not shown). 
Furthermore, monocytes derived from TLR2
-/-
 mice showed decreased sensitivity to B16 CM, 
suggesting a TLR2-dependent signaling mechanism for regulating TNF-α secretion (and 
ultimately PD-L1 upregulation) by TAM. We found that the removal of versican from B16 CM 
significantly suppressed upregulation of TNF-α production and PD-L1 expression by monocytes 
cultured with B16 CM, indicating that versican produced by tumor cells plays a central role in 
regulating monocytes. 
Interestingly, monocytes from TLR2
-/-
 mice exhibited no decrease in TNF-α secretion 
compared to WT monocytes following exposure to 4T1 CM. This finding suggests an alternative 
mechanism by which CM from 4T1 cells induced TNF-α secretion. One possibility is production 
of MMP-3 by 4T1 cells, as they have been reported previously to produce MMP-3 in culture, 
which in turn was shown to induce macrophages to produce TNF-α
186,187
.  
Furthermore, we observed large numbers of macrophages expressing TNF-α and PD-L1 
within tumor tissues, thus providing in vivo validation of the in vitro observations. We also 
observed that growth of B16 tumors was significantly suppressed in TNFR
-/-
 mice with 
decreased expression of PD-L1 by TAM and dendritic cells but not on tumor cells, indicating the 
overall importance of PD-L1 expression by TAM in the regulation of tumor growth. The 
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reduction in PD-L1 expression by TAM from tumors in TNFR
-/-
 mice would also be expected to 
enhance anti-tumor immunity, which could account for the reduced tumor growth. These data 
provide additional in vivo support for the existence of a TNF-α – PD-L1 immune regulatory 
pathway in tumors.  
 In summary, our studies provide evidence for a new immune pathway for regulation of 
PD-L1 expression by monocytes and macrophages in tumor tissues, and potentially in other 
organs undergoing inflammatory insults. This pathway requires the release of pro-inflammatory 
mediators (such as versican) from tumors, plus the presence of inflammatory monocytes and 
macrophages that respond to the inflammation-associated signals by releasing TNF-α in a TLR2-
dependent mechanism. The local release of TNF-α in turn leads to upregulation of PD-L1 
expression, thereby triggering local immune suppression. Interruption of this pathway could have 
important therapeutic implications as a means of enhancing anti-tumor immunity. Thus, 
improved understanding of this and other pathways for regulation of PD-L1 expression by 
inflammatory monocytes TAM in tumor tissues will be important to the design of newer 










Tumor-associated macrophages (TAM) express high levels of PD-L1 and contribute to 
the immune-suppressive tumor microenvironment. While the role of PD-L1 signaling to PD-1 to 
induce T cell exhaustion is well established, much less is known about whether PD-L1 signals 
directly to macrophages and how these signals affect TAM function. Therefore, we used in vitro 
and in vivo models to investigate PD-L1 signaling in macrophages and the effects of sCD80, 
sPD-1, and PD-L1 blocking antibody on TAM phenotype. We observed that incubation of 
macrophages with PD-L1 antibody induced proliferation and spreading, along with upregulation 
of co-stimulatory molecules and spontaneous inflammatory cytokine production. Similar changes 
were observed in macrophages incubated with sCD80, in PD-L1
-/-
 macrophages, and to a lesser 
extent in macrophages incubated with sPD-1. Furthermore, treatment with PD-L1 antibody 
upregulated mTOR pathway activity and RNAseq revealed an inflammatory macrophage 
phenotype. In vivo, significant tumor infiltration with macrophages was observed following 
treatment with PD-L1 antibody, along with evidence of macrophage activation. Studies 
conducted in Rag
-/-
 mice showed upregulated co-stimulatory molecule expression by TAMs and 
reduced tumor growth in mice treated with PD-L1 antibody. Moreover, combined PD-1/ PD-L1 
antibody treatment of mice with established melanomas elicited complete tumor elimination in 
half of the animals. These findings suggest that PD-L1 delivers a constitutive signal in 
macrophages to suppress mTOR pathway activity, leading to an immune-suppressive phenotype. 
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These results also suggest that PD-L1 antibodies induce qualitatively different anti-tumor effects 




PD-L1 is often overexpressed by tumor tissues, and the level of expression by tumors is 
frequently associated with prognosis and response to treatment with PD-1 therapeutic 
antibodies
188-190
. Notably, a number of studies agree that the density of PD-L1-expressing 
macrophages in tumors is predictive of the efficacy of both PD-1 and PD-L1 antibody 
therapy
99,102,103
. For example, in some cases, response rates as high as 80% have been observed 
in patients where macrophages were positive for PD-L1 expression
99
. PD-L1 is a 290-amino acid 
transmembrane glycoprotein with a short cytoplasmic tail and has historically been viewed 
simply as a ligand for PD-1
191,192
. However, there has been emerging evidence suggesting that 
direct signaling by PD-L1 may play a role in regulating tumor growth and biology. 
For example, PD-L1 signaling has been shown to promote epithelial-to-mesenchymal 
transition in several tumor types
193-195
. Conversely, downregulation of PD-L1 expression was 
associated with decreased tumor metastasis
193,194
. Other groups have reported that PD-L1 acts as 
an anti-apoptotic receptor in response to Fas ligation, and that PD-L1 was also associated with 
cancer stem cell proliferation
196,197
. In addition, upregulation of PD-L1 expression on tumor cells 
resulted in increased resistance to apoptosis upon treatment with chemotherapy
198
.  
PD-L1 signaling also regulates cellular functions. Tumor cell metabolism was shown to 
be regulated by PD-L1 through Akt/mTOR phosphorylation and signaling, and PD-L1 blockade 
resulted in decreased levels of glucose uptake and glycolysis
199
. This study also found that tumor 
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cells showed decreased glycolysis upon knockdown of PD-L1, suggesting that PD-L1 signals 
constitutively and that this activity may be blocked by PD-L1 antibodies. Furthermore, studies 
have reported an increase in ERK- and mTOR-mediated proliferation and survival of tumor cells 
following ligation of PD-L1 with human PD-1 or in culture with PD-L1-expressing T cells
200,201
. 
Ligation of PD-L1 on dendritic cells using soluble PD-1 led to a downregulation of maturation-
associated markers, and a murine macrophage cell line showed a more regulatory, immune-
suppressive phenotype when treated with a PD-L1 antibody
202,203
. Little is known, however, 
regarding the effects of PD-L1 signaling in macrophages in the tumor microenvironment (TME).  
The goal of the present study was to investigate the role that PD-L1 expressed by tumor-
associated macrophages (TAM) plays in regulating the biological functions of macrophages in 
the TME. TAM often express high levels of PD-L1, and we recently reported that PD-L1 
expression by TAM was regulated primarily by locally produced TNF-α
204
. In a screen of several 
different tumors in humans, PD-L1-expressing macrophages were found to be more abundant 
than PD-L1-expressing tumor cells
99
. Other studies found that treatment with PD-L1 antibody 
induced antitumor activity even in models where PD-L1 was not expressed by the tumor cells 
themselves, suggesting that PD-L1 expression by macrophages may be more important to the 
overall effect of PD-L1 antibody treatment
102,103
. We hypothesized that this anti-tumor activity is 
mediated by changes in tumor macrophages following treatment with PD-L1 antibody. 
Therefore, we conducted in vitro studies to assess the impact of PD-L1 antibody, soluble PD-1, 
and soluble CD80 (another ligand of PD-L1
21
) on macrophage survival and activation. We also 
conducted global gene expression profiling of PD-L1 antibody-treated macrophages. In addition, 
the effects of PD-L1 antibody treatment on TAM phenotype were assessed in mouse tumor 
models, as well as the effects of combined PD-1 and PD-L1 antibody treatment.  
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Materials & Methods. 
Mice. Wild-type C57Bl/6 mice and Rag1
tm1Mom
/J mice were purchased from Jackson 
Laboratories and cared for in accordance with institutional and NIH guidelines. Mice were 
inoculated subcutaneously in the flank with 1 x 10
5
 B16.F10 melanoma cells or PyMT breast 
carcinoma cells. On Day 7, B16-inoculated mice were randomly placed into 3 treatment groups 
and tumor take between the groups was verified to be statistically similar. They received 
intraperitoneal injections of PBS, 250 ug isotype (BioXcell, West Lebanon, NH) or PD-L1 
antibody (BioXcell, clone 10F.9G2) in a volume of 100 ul every 3 days for 9 days. Treatment for 
PyMT-inoculated Rag
-/-
 mice started on Day 18, and mice received injections of PBS, 100 ug 
isotype or PD-L1 antibody every 3 days for 9 days. Mice were humanely euthanized when the 
first tumors reached a size of 15 mm in diameter, according to Institutional Animal Care and Use 
Committee protocol. For combination blockade of PD-1 and PD-L1, mice were inoculated 
similarly and randomized on Day 7. They received intraperitoneal injections of 100 ug PD-1 
antibody (BioXcell, clone RPM1-14), 100 ug PD-L1 antibody, or 100 ug PD-1 + 100 ug PD-L1 
antibodies every 3 days for 9 days then once a week for a total of 68 days. Mice were euthanized 
individually as the tumors reached 15 mm in diameter for a survival study, and tumor area was 
calculated as length x width. Remaining mice were euthanized at 68 days and verified to be 
tumor-free.  
 
Monocyte isolation and macrophage culture. Tibias and femurs were collected from healthy 
mice and bone marrow cells were harvested as described previously
204
. Tissues from PD-L1
-/-
 
C57Bl/6 mice were a kind gift from Raphael Nemenoff and Howard Li (University of Colorado, 
Denver). Bone marrow cells were cultured in PermaLife bags (OriGen Biomedical, Austin, TX) 
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with 10 ng/ml rM-CSF (R&D Systems, Minneapolis, MN) for one week. 50,000 M-CSF-
cultured macrophages were washed with medium to remove M-CSF and plated in 96-well 
polystyrene cell culture plates (Corning, New York, NY) for 48 hours with or without treatment 
before use in experiments. Adherent bone marrow-derived macrophages were then harvested by 
pipetting with ice-cold 2mM EDTA (ThermoFisher Scientific, Waltham, MA) in PBS. 
For enrichment of human macrophages, monocytes were selected from peripheral blood 
mononuclear cells by adherence overnight in cell culture plates and cultured for one week in 10 
ng/ml rhM-CSF (Peprotech, Rocky Hill, NJ).  
 
Reagents for treatment of bone marrow-derived macrophages. PD-L1 antibody (BioXcell, clone 
10F.9G2) and irrelevant isotype-matched control antibody (BioXcell) were used at 100 ug/ml, 
which represents the reported minimum desired plasma antibody concentration for patients 
treated with PD-L1 antibody
99
. These antibodies were verified by the manufacturer to contain 
less than 0.002 EU/ug of endotoxin. A rat anti-mouse CD11b antibody (eBioscience, Waltham, 
MA, clone M1/70) was used as a macrophage specific antibody, but with a function unrelated to 
that of PD-L1, for in vitro antibody studies. For human macrophages, PD-L1 antibody 
(Biolegend, clone 29E.2A3) and irrelevant isotype-matched control antibody (Biolegend, San 
Diego, CA) were used at 200 ug/ml. 
Recombinant mouse soluble PD-1 chimera protein with a human IgG1 Fc portion was 
obtained from R&D systems and used at 100 ug/ml to match the PD-L1 antibody concentration. 
Recombinant mouse soluble CD80 chimera protein with a human Fc portion was obtained from 
Biolegend and used at 100 ug/ml. Donkey anti-human IgG Fc from Jackson Immunoresearch 
(West Grove, PA) was used at 10 ug/ml to crosslink sPD-1 and sCD80, according to the 
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manufacturer’s suggestions. CD16/CD32 Fc blocking antibody (eBioscience) was used at 100 
ug/ml to match the PD-L1 antibody concentration. 
 Rapamycin (Sigma-Aldrich, St. Louis, MO) was used at 10 ug/ml as an indirect inhibitor 
of mTOR signaling and Torin2 (Sigma-Aldrich) was used at 0.15 uM as a direct inhibitor of 
mTOR
205,206
. IFN-g and TNF-a from Peprotech were used to stimulate macrophages at 10 ng/ml.  
 
Tumor cell lines. B16.F10 melanoma cells and PyMT breast carcinoma cells were obtained from 
ATCC and screened by PCR to ascertain that they were of murine origin, and free of 
mycoplasma contamination.  
 
Tissue preparation for flow cytometry. Tumor tissues processed to a single cell suspension, as 
described previously
204
. Cells were immunostained using the following antibodies: Invitrogen: 
CD45 Pacific Orange (MCD4530), eBioscience: PD-L1 PE (clone MlH5), CD11b Pacific Blue 
(clone M1/70), CD86 PE (clone GL1), and MHCII APC (clone M5/114.15.2), Abd Serotec: F4-
80 APC (clone Cl:A3-1), BD Pharmingen: Ly6C biotin (clone AL-21) and Ly6G FITC (clone 
1A8). Cells were also stained with appropriately-matched isotype antibodies to assure specificity 
of immunostaining.  
To quantitate intracellular cytokine production, macrophages were treated with protein 
secretion inhibitor Brefeldin (Biolegend) for 4 hours prior to staining. The cells were fixed with 
4% PFA (Affymetrix, Santa Clara, CA) and permeabilized with 0.25% Saponin in FACS buffer 
(1% BSA in PBS with 0.05% sodium azide) prior to immunostaining for IL-12 PE (BD 
Pharmingen, San Jose, CA) and TNF-α PE (eBioscience, clone MP6-XT22). To measure mTOR 
pathway activity, polyclonal antibodies from Cell Signaling Technologies (Danvers, MA) were 
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used to stain for intracellular levels of mTOR and p-mTOR, and secondary donkey anti-rabbit 
IgG FITC (Jackson Immunoresearch) was used to detect primary antibody binding. 
Human macrophages were immunostained with CD14 APC (Bio-Rad, Hercules, CA, 
clone TUK4), CD40 PE (eBioscience, clone 5C3) and CD86 FITC (BD Pharmingen, clone FUN-
1). Appropriately-matched isotype control antibodies were also used to assure specificity of 
immunostaining.  
 
Immunofluorescent tissue staining and imaging. Tumor tissues were prepared for 
immunofluorescent staining as described previously
204
. Primary antibodies for F4-80 (AbD 
Serotec, Raleigh, NC clone Cl:A3-1) and MHC II (eBioscience, clone M5/114.15.2) were used. 
Controls included immunostaining with appropriate concentrations of irrelevant isotype-matched 
antibodies.  
 
Proliferation assay. A Click-iT assay kit was used to measure proliferation of macrophages 
(ThermoFisher Scientific). EdU was added the same day as PD-L1 antibody treatment to be 
incorporated into proliferating cells for 48 hours prior to analysis. Cells were then detached, 
stained, and proliferation was evaluated by flow cytometry or immunofluorescent imaging as 
described above. 
 
Western blotting. A standard western blotting protocol from Bio-Rad was followed. Briefly, 
macrophages were treated with medium, irrelevant isotype antibody, or PD-L1 antibody for 5 
hours. Samples were prepared under non-reducing, denaturing conditions and 6 ug total protein 
was loaded into a gel (BioRad). Polyclonal antibodies from Cell Signaling Technologies for Akt 
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and pAkt and were used to probe for their respectable proteins, followed by peroxidase-
conjugated goat anti-rabbit secondary antibody (Jackson Immunoresearch). An antibody for b-
actin (Sigma-Aldrich, clone AC-15) was used as a loading control, followed by donkey anti-
mouse secondary antibody (Jackson Immunoresearch). Densitometric analysis to quantify band 
area was completed using ImageJ software and values were normalized to b-actin. 
 
RNAseq. Bone marrow was collected from 9 mice and cultured as described above. After one 
week, macrophages were treated with medium only, irrelevant isotype or PD-L1 antibody 
antibodies for 24 hours. Total RNA was extracted using RNeasy micro Kit (Qiagen, Hilden, 
Germany) and RNA was submitted to Novogene (Sacramento, CA) for RNAseq. Samples were 
tested for quality control by Agilent 2100 Bioanalyzer system and by agarose gel electrophoresis. 
Sample RNA integrity number ranged from 7 to 8.9. After the QC procedures, mRNA was 
enriched using oligo(dT) beads and fragmented randomly, then cDNA synthesized by using 
mRNA template and random hexamers primer, after which a custom second-strand synthesis 
buffer (Illumina, San Diego, CA), dNTPs, RNase H and DNA polymerase I were added to 
initiate the second-strand synthesis. Second, after a series of terminal repair, a ligation and 
sequencing adaptor ligation, the double-stranded cDNA library was completed through size 
selection and PCR enrichment. Library was qualified by Agilent 2100 to test the insert size, then 
Q-PCR was used to quantify the library effective concentration. Quantified libraries were run on 
Illumina PE150 (HiSeq) with 250~300bp insert cDNA library for 20M raw reads/sample. Raw 
data was filtered by removing reads containing adapters and reads containing N > 10% by 
Novogene, Phred score >30. 
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The filtered reads obtained by RNAseq from Novogene were analyzed using Partek® 
Flow® software, version 6.0. Filtered reads were aligned with STAR pipeline aligned against 
RefSeq Transcripts 83 - 2017-11-01 mouse whole genome. Counts were calculated using Partek 
E/M. Transcript counts were normalized using Partek total count method per sample and then an 
offset of 0.0001 was added to avoid zero counts. Normalized transcript counts were used to 
generate PCA plot. To detect differentially expressed genes, ANOVA was performed on the 
normalized transcript counts. Differentially expressed genes were filtered using p-value with 
false discovery rate ≤ 0.05 and fold change ≤ -2 or ≥ 2. Further biological interpretations 
including gene ontology enrichment and pathway analysis was performed. Functional analysis 
was generated using Ingenuity pathway analysis (IPA, Qiagen Inc.) Version 01-12. IPA analysis 
settings included stringent filters for molecules and relationships in mouse, experimentally 
observed confidence, and filtered for tissue and primary cells.  
 
Statistical analysis. Statistical comparisons between those data sets with two treatment groups 
were done using nonparametric t-tests (Mann-Whitney test). Comparisons between 3 or more 
groups were done using ANOVA, followed by Tukey multiple means post-test. Analyses were 
done using Prism7 software (GraphPad, La Jolla, CA) and statistical significance was determined 
for p < 0.05. Statistical comparisons for survival analysis were done with Kaplan Meier and log 
rank (Mantel Cox) tests, with statistical significance determined as p < 0.01. 
 
Results. 
Macrophage proliferation and size increase with PD-L1 antibody treatment. To first examine the 
effects of PD-L1 antibody on macrophage phenotype and function, we used in vitro generated 
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macrophages since they express high levels of PD-L1 (Figure 5.1A). The most striking early 
observation was that macrophages cultured in the presence of PD-L1 antibody, were markedly 
more numerous and larger than control macrophages (Figure 5.2A). The increased density of 
macrophages cultured with PD-L1 antibody could represent the effects of increased proliferation, 
survival, activation and spreading, or a combination of all 3.  
To determine the cause of the increased macrophage density, we first assessed 
proliferation of macrophages incubated with PD-L1 antibody or control antibodies (Figure 
5.2B). We found that macrophages taken out of M-CSF continued to proliferate when treated 
with PD-L1 antibody compared to both untreated and irrelevant antibody-treated cells (Figure 
5.2C and 5.2D). Furthermore, live cell measurements of macrophages cultured with PD-L1 
antibody revealed that macrophage size and numbers increased significantly over time (Figure 
5.2E and 5.2F). In addition, increased macrophage survival was demonstrated using the MTT 
assay (Figure 5.2G). Hence, macrophages treated with PD-L1 antibody demonstrated changes in 
proliferation, survival and size. 
 
Figure 5.1 PD-1 and PD-L1 expression by bone marrow-derived macrophages. Bone 
marrow monocytes were cultured with M-CSF for one week for the enrichment of macrophages 
and plated for adherent culture overnight. They were then detached and processed for flow 
cytometric analysis of PD-L1 (A), PD-1 (B), and CD80 (C) expression. Histograms are shown in 




Figure 5.2 Macrophage proliferation and size increase with PD-L1 antibody treatment. 
Macrophages were treated with medium only, irrelevant isotype or PD-L1 antibody. After 6 
days, images of the macrophages were taken (A). Proliferation was measured using EdU 
incorporation (B) and quantified using flow cytometric analysis (C) to be statistically compared 
using one-way ANOVA and Prism7 software (D). Changes in confluence (E) and average cell 
sizes (F) were measured every 3 hours for the 6 days with an IncuCyte ZOOM live cell imaging 
system. Lastly, an MTT was performed to measure survival of the cells and mean absorbances of 
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MTT substrate were compared statistically with one-way ANOVA and Prism7 software (G). 
Statistically significant differences were denoted as P-value **** < 0.0001. Similar results were 
obtained in 3 independent experiments.  
 
PD-L1 antibody treatment induces macrophage activation. Studies were conducted next to 
determine whether PD-L1 antibody treatment stimulated macrophage activation, given the 
appearance of these macrophages in Figure 1. Compared to isotype antibody-treated 
macrophages, PD-L1 antibody treatment upregulated expression of co-stimulatory molecules 
CD86 and MHC II, consistent with macrophage activation (Figure 5.3A). This effect was found 
to be titratable with increasing concentrations of PD-L1 antibody (Figure 5.3B) and the 
macrophage changes were first apparent after 48 hours of treatment (Figure 5.3C). PD-L1 
antibody-treated macrophages also spontaneously increased production of TNF-α and IL-12 
(Figure 5.3D), which suggested that PD-L1 antibody treatment skewed the macrophages 
towards a more inflammatory phenotype.  
 
Figure 5.3 PD-L1 antibody treatment induces macrophage activation. Macrophages were 
treated with medium only, irrelevant isotype or PD-L1 antibody for 48 hours. They were stained 
for co-stimulatory molecule expression (CD86, MHCII) by flow cytometry and the geometric 
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mean fluorescence intensity (gMFI) is shown as fold increase over an irrelevant isotype stain 
(A). PD-L1 antibody was titrated (B) and macrophages were harvested at different time points 
following treatment with 100 ug/ml in (C). Finally, macrophages were permeabilized for staining 
of intracellular cytokines (IL-12 and TNF-a) by flow cytometry in (D). Fold changes were 
compared using one-way ANOVA and Prism7 software. Statistically significant differences were 
denoted as P-value ** < 0.005, *** < 0.0005, and **** < 0.0001. These data are representative 
of 3 experiments with similar results. 
 
Similar changes were observed with human macrophages. Specifically, we found changes 
in morphology of macrophages following PD-L1 antibody treatment (Figure 5.4A) as well as 
upregulated expression of CD40 and CD86 (Figure 5.4B).  
 
Figure 5.4 PD-L1 antibody treatment of human macrophages results in phenotypic changes 
consistent with those seen in murine macrophages. Macrophages were treated with medium 
only, an irrelevant isotype antibody, or PD-L1 antibody for 48 hours, and images were taken of 
the cells to assess changes in morphology (A). Surface expression of co-stimulatory molecules 
(CD40 and CD86) was compared by flow cytometry with two-way ANOVA and Prism7 
software. Statistically significant differences were denoted as P-value *** < 0.0005 and **** < 
0.0001, with similar results obtained in 2 independent experiments. 
 
Binding of CD80 alters macrophage phenotype and activation more strongly than PD-1. We 
next wanted to see if the ligands for PD-L1 could induce the same effect as PD-L1 antibody 
treatment. To this end, we treated macrophages with crosslinked soluble PD-1 or CD80 to mimic 
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the effects of interaction with T cells expressing PD-1 or other macrophages expressing CD80. 
Treatment with both sPD-1 and sCD80 induced a change in macrophage morphology (Figure 
5.5A) and also produced larger cells, consistent with the changes induced by incubation with PD-
L1 antibody (Figure 5.5B). The sPD-1 treated macrophages increased expression of the co-
stimulatory molecule CD86, but not MHCII, suggesting partial macrophage activation. However, 
treatment with sCD80 greatly increased expression of CD86, MHC II, and TNF-α (Figure 5.5C). 
Of note, we found that the macrophages do not express PD-1 either in our culture system 
(Figure 5.1B), or directly taken from bone marrow, lungs, or spleens of healthy mice (data not 
shown). This is consistent with a recent paper that shows induction of PD-1 expression only 
upon migration into the tumor environment
207
. Furthermore, we observed that the macrophages 
expressed membrane-bound CD80 (Figure 5.1C) but not soluble CD80 in our culture system 
(data not shown). These data suggest that CD80 may be the strongest ligand for PD-L1, and that 
treatment with PD-L1-specific antibodies mimics this ligand-receptor interaction to activate 
macrophages. 
 
Fc receptor engagement and treatment with a macrophage integrin antibody fail to activate 
macrophages. To assess the specificity of the observed changes mediated by PD-L1 antibody, 
macrophages were treated with a macrophage-specific antibody (CD11b) or with CD16/32 Fc 
receptor antibody. Macrophage morphological changes were not observed following treatment 
with CD11b antibody or Fc-receptor antibodies (Figure 5.6). Changes in macrophage 
proliferation or expression of co-stimulatory molecules were also not observed (Figure 5.7). 
Furthermore, pre-treatment of the macrophages with anti-Fc receptor antibody prior to 
incubation with PD-L1 antibody did not abrogate the changes mediated by PD-L1 antibody alone  
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Figure 5.5 Treatment of macrophages with sCD80 alters macrophage phenotype and 
activation more strongly than crosslinked sPD-1. Macrophages were treated with crosslinked 
sPD-1 or sCD80 for 48 hours, and images were taken of the cells to assess changes in 
morphology (A). Size of the cells was quantified by flow cytometry in (B) and compared using 
nonparametric t-test and Prism7 software. In (C), co-stimulatory molecule expression (CD86 and 
MHC II) and intracellular TNF-a production were measured by flow cytometry. Geometric 
mean fluorescence intensity (gMFI) is shown as fold increase over an irrelevant isotype stain, 
and fold changes were compared using two-way ANOVA and Prism7 software. Statistically 
significant differences were denoted as P-value ** < 0.005, *** < 0.0005, and **** < 0.0001. 





Figure 5.6 Morphology of macrophages treated with control antibodies. Macrophages were 
incubated with medium only, irrelevant isotype antibody, a macrophage-specific antibody 
(CD11b), Fc-blocking antibody, or pre-treated with Fc-blocking antibody for 1 hour before 
treatment with PD-L1 antibody. Photographs of the macrophages were taken after 48 hours with 




Figure 5.7 Control antibody treatments for macrophage proliferation and co-stimulatory 
molecule expression. Macrophages were incubated with irrelevant isotype antibody, 
macrophage-specific antibody (CD11b), Fc-blocking antibody, or pre-treated with Fc-blocking 
antibody before treatment with PD-L1 antibody. After 48 hours, proliferation measured by EdU 
incorporation and surface expression of co-stimulatory molecules (CD86 and MHC II) was 
compared by flow cytometry with two-way ANOVA and Prism7 software. Statistically 
significant differences were denoted as P-value **** < 0.0001, and similar results were obtained 
in 2 independent experiments.   
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(Figures 5.6 and 5.7). As a positive control for these studies, macrophages were stimulated with 
IFN-g and TNF-a overnight (data not shown).  
 
PD-L1 signals constitutively in macrophages to inhibit mTOR pathway signaling. We next 
sought to determine whether PD-L1 signals constitutively in macrophages or if PD-L1 signaling 
first requires ligation. To address this question, bone marrow derived macrophages were 
generated from PD-L1
-/-
 mice. Macrophages from PD-L1
-/-
 mice exhibited increased baseline 
proliferation (Figure 5.8A) and upregulated MHC II expression compared to wild-type 
macrophages (Figure 5.8B). These results are consistent with the concept that the PD-L1 
molecule signals constitutively and negatively in macrophages, and that ligation with soluble 
CD80 or with certain PD-L1 antibodies inhibits this negative signaling, resulting in macrophage 
proliferation, survival and spontaneous activation.  
Previous studies have reported involvement of the mTOR pathway in PD-L1 signaling in 
tumor cells
199-201
, and mTOR signaling has been found to regulate metabolic programming of 
antigen presenting cells in normal tissues
208
. Therefore, we investigated the effects of mTOR 
inhibitors on macrophage activation following treatment with PD-L1 antibody. Treatment of PD-
L1 antibody-cultured macrophages with either rapamycin (non-specific mTOR pathway 
inhibitor) or torin2 (targeted mTOR inhibitor)
205,206
 dampened the changes induced by PD-L1 
antibody treatment. Specifically, treatment with rapamycin and torin2 significantly blocked PD-
L1 antibody-induced proliferation, TNF-α production, and expression of MHC II compared to 
macrophages treated with PD-L1 antibody alone (Figure 5.8C). We next assessed Akt and 
mTOR phosphorylation, since it was previously reported that PD-L1 signaling maintains mTOR 
pathway signaling in tumor cells
199
. We found increased p-Akt (Figure 5.8D) and p-mTOR
92	
 
Figure 5.8 PD-L1 signals constitutively in macrophages to inhibit mTOR pathway signaling. Macrophages from wild-type and 
PD-L1
-/-
 mice were cultured for one week as described in Methods. Proliferation was measured by EdU incorporation (A) and co-
stimulatory molecule expression (CD86 and MHC II) was measured by flow cytometry (B). In (C), wild-type macrophages were 
treated with PD-L1 antibody in combination with mTOR inhibitors rapamycin and torin2 for 48 hours prior to phenotyping by flow 
cytometry. In (D), lysates from wild-type macrophages treated with medium, irrelevant isotype or PD-L1 antibody were used for 
assessment of Akt phosphorylation by western blot. Lastly, wild-type macrophages treated with medium, irrelevant isotype or PD-L1 
antibody were also used for intracellular staining of mTOR and p-mTOR levels by flow cytometry (E). Statistical comparison for (A) 
was completed using nonparametric t-test, for (B) and (C) using two-way ANOVA, and for (E) using one-way ANOVA. All statistical 
comparisons were completed using Prism7 software. Statistically significant differences were denoted as P-value *** < 0.0005 and 
**** < 0.0001, and similar results were obtained in 2 additional, independent experiments.
93	
(Figure 5.8E) in macrophages treated with PD-L1 antibody. Together, these results suggest that 
PD-L1 constitutively signals to block mTOR pathway signaling. Genetic elimination of PD-L1 
expression or blockade of signaling by PD-L1 antibody appears to remove inhibition of this 
signaling pathway, resulting in the aforementioned macrophage changes.  
 
Transcriptome profiling of PD-L1 antibody-treated macrophages showed inflammatory 
phenotype, increased survival and proliferation, and decreased apoptosis. To gain a 
comprehensive understanding of the changes to macrophages mediated by PD-L1 antibody 
treatment, RNAseq was conducted. We found that the gene expression profiles of macrophages 
treated with PD-L1 antibody were quite distinct from macrophages treated with isotype antibody 
or untreated macrophages (Figure 5.9A). We identified 1823 differentially expressed genes 
following PD-L1 antibody treatment, with 643 genes upregulated and 1180 genes downregulated 
compared to isotype antibody treatment (Figure 5.9B).  
 
Figure 5.9 Transcriptome profiling of PD-L1 antibody-treated macrophages showed 
inflammatory phenotype, increased survival and proliferation, and decreased apoptosis. 
Macrophages were treated with medium only, irrelevant isotype antibody, or PD-L1 antibody for 
24 hours prior to RNA extraction for RNA sequencing analysis. The PCA plot (A) depicts the 
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relationship and grouping of the samples based on global gene expression with medium only in 
red, isotype antibody in blue, and PD-L1 antibody in yellow. The volcano plot (B) shows the 
number of genes up- and down-regulated on PD-L1 antibody-treated macrophages compared to 
isotype antibody-treated macrophages for P value with FDR ≤ 0.05 and fold change ≤ -2 (left, 
green) or ≥ 2 (right, red). Gene Ontology enrichment analysis was used to classify all 
significantly upregulated (C) and downregulated (D) genes into biological processes, with the 
enrichment score on the x-axis. These data were generated using macrophages from 9 mice, with 
3 mice in each treatment group. 
 
To investigate the likely biological functions regulated by PD-L1, we used Ingenuity 
Pathway Analysis (IPA) software. We first identified the top differentially expressed genes by 
PD-L1 antibody-treated macrophages compared to those treated with isotype antibody. Figure 
5.10A first depicts the 25 most upregulated genes by PD-L1 antibody-treated macrophages, 
which were increased up to 115-fold over isotype antibody-treated macrophages. The most 
highly upregulated gene was found to be Serpinb2, one of the most highly induced macrophage 
genes following LPS stimulus where it prevents macrophage death
209
. Serpinb2-deficient mice 
show impaired macrophage infiltration and an alternative/anti-inflammatory macrophage 
phenotype
210
, suggesting an important role for this protease in promoting inflammatory 
macrophage function. The second most upregulated gene was Saa3 (serum amyloid A3), which 
increases in response to acute inflammation and drives pro-inflammatory macrophage 
differentiation
211,212
. Not surprisingly, classical pro-inflammatory macrophage markers Cd38, 
Il1a, Nos2, and Il6 were also upregulated. Other upregulated genes include Slfn4 and Slc7a2, 
which are found to be upregulated only during macrophage activation
213,214
, and upregulated 
chemotaxis genes Ccl7 (MCP3), Cxcl3 (MIP-2b), Ccl2 (MCP-1), and Fpr2
215
. Interestingly, 
upregulated Fpr1 is reported to only increase inflammatory macrophage chemotaxis while anti-
inflammatory macrophages are unresponsive to FPR1
216
. Finally, upregulated Dll4 and Tarm1 




Figure 5.10A next depicts the top 25 downregulated genes in PD-L1 antibody-treated 
macrophages decreased by over 50-fold compared to isotype antibody-treated macrophages. Of 
these, a gene characteristic of anti-inflammatory macrophages (Slco2b1) was strongly 
downregulated
219
. We also found downregulated expression of Angptl4, which codes for a 
protein that is decreased in pro-inflammatory macrophages
220
. Finally, downregulated Pparg, 
Tle1, and Clec10a further show a suppressed anti-inflammatory phenotype of these macrophages 
and suggest a push towards an inflammatory state mediated by PD-L1 antibody treatment
221-223
.  
IPA analysis revealed that the top 10 signaling pathways altered by PD-L1 antibody 
treatment included upregulated inflammatory pathways, a downregulated anti-inflammatory 
pathway, an upregulated survival and proliferation pathway, and downregulated apoptosis 
pathways (Figure 5.10B). The top pathway with the strongest statistical significance was the 
“Type I Diabetes Mellitus”, which involves increased key components of the macrophage 
inflammatory response TNF-α, iNOS, and IL-1b (Figure 5.10B) The second pathway was 
“LXR/RXR activation”, which also involves increased TNF-α as well as strongly upregulated 
inflammatory mediators iNOS, IL-1, IL-1b and IL-6 (Figure 5.10B) “PPAR signaling” was 
downregulated with decreased PDGF, which promotes an immune-suppressed environment
224
, 
and decreased PPARγ, which skews macrophages towards an anti-inflammatory phenotype
221,225
 
(Figure 5.10B). “TNFR2 signaling” was upregulated, showing increased TNFR2 and A20 that 
lead to increased proliferation and survival
226,227
 (Figure 5.10B). Also downregulated were two 







Figure 5.10 Ingenuity Pathway Analysis of PD-L1 antibody-treated macrophages showed inflammatory phenotype, increased 
survival and proliferation, and decreased apoptosis. Ingenuity Pathway Analysis of significantly up- and down-regulated genes 
was next used to identify altered signaling pathways. (A) depicts the top 25 upregulated (left, red) and downregulated (right, green) 
genes and the genes were classified into signaling pathways in (B), with the yellow line depicting statistical significance. Upregulated 
values are shown in red and downregulated values in green. These data were generated using macrophages from 9 mice, with 3 mice 
in each treatment group. 
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Accumulation of activated macrophages in tumors following PD-L1 antibody treatment and 
slowed tumor growth in RAG
-/-
 mice. The in vivo effects of PD-L1 antibody treatment on TAM 
were investigated in mice with established B16 tumors. This tumor model was chosen due to 
recent studies conducted in our lab which showed high expression of PD-L1 on macrophages in 
B16 tumor tissues
204
. Treatment of mice with PD-L1 antibody triggered a significant increase in 
numbers of TAM, while the numbers of macrophages in the spleen and lymph nodes of PD-L1 




 T  cells 
in these tumors were also increased (Figure 5.11B). In agreement with our in vitro data, TAM 
from PD-L1 antibody-treated mice had significantly increased MHC II expression (Figure 
5.11C). There was also a large overall increase in F4-80
+
 macrophages in tumor tissues, 
including MHC II
+
 macrophages (Figure 5.11D).  
 To demonstrate the macrophage response to PD-L1 antibody treatment in both a different 
tumor model and in the absence of T cells, PyMT tumors were implanted into Rag
-/-
 mice. There 
was no difference in the number of TAM in this tumor model (Figure 5.11E). However, 
increased numbers of TAM from mice that were treated with PD-L1 antibody expressed co-
stimulatory molecules CD86 and MHC II suggesting activation of these cells (Figure 5.11F). 
Furthermore, PD-L1 antibody treatment slowed tumor growth in mice compared to irrelevant 
antibody controls (Figure 5.11G). These results suggest a significant protective effect mediated 
by TAM that are activated by PD-L1 antibody treatment.    
 
Combined therapy with PD-1/PD-L1 antibodies induces early tumor regression and tumor-free 
survival. Because PD-L1 antibody treatment appeared to exert other effects on TAM in addition 
to simply blocking the PD-1 interaction on T cells, we predicted that combined treatment with  
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Figure 5.11 Accumulation of activated macrophages in tumors following PD-L1 antibody 
treatment and inhibited tumor growth in Rag
-/-
 mice treated with PD-L1 antibody. B16 
melanoma cells were injected into C57Bl/6 mice and the mice were treated with PBS, irrelevant 
isotype or PD-L1 antibody. Tumor, spleen, and lymph node tissue was harvested for flow 
cytometric analysis of macrophage populations (A) and percentages of tumor macrophages and T 
cells are shown in (B). We also measured surface expression of tumor macrophage MHC II (C) 
by flow cytometry, and tumor tissues were stained for F4-80 (green) and MHC II (red) 
expression before counterstaining with DAPI (blue) for imaging at 10X magnification (D). 
Statistical comparison of cell numbers and expression of surface markers were compared by two-
way ANOVA using Prism7 software, and these data are representative of 2 repeated experiments 
with 4 mice in each group. Next, PyMT breast carcinoma cells were injected into Rag
-/-
 mice and 
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the mice were treated with irrelevant isotype or PD-L1 antibody. Tumor tissue was harvested for 
flow cytometric analysis of macrophage percentages (E) and surface expression of costimulatory 
molecules (F). Tumor growth was also compared (G). Statistical comparison of cell numbers was 
completed using nonparametric t-test and both expression of surface markers and tumor sizes 
were compared by two-way ANOVA using Prism7 software. Statistically significant differences 
were denoted P-value * < 0.05, ** < 0.005, *** < 0.0005, and **** < 0.0001, and these are 
pooled data from 2 experiments for a total of 6 mice in each group.  
 
PD-1/PD-L1 antibodies would induce significantly greater antitumor activity than treatment with 
either antibody alone. To address this question, B16 melanoma tumor-bearing mice with 
palpable cutaneous tumors were treated with PD-1 antibody, PD-L1 antibody, or a combination 
of PD-1 and PD-L1 antibodies. We observed that treatment with PD-1 and PD-L1 antibodies 
alone resulted in delayed tumor growth and slightly improved survival compared to sham-treated 
mice (Figure 5.12A and 5.12B). Remarkably, combination PD-1/PD-L1 antibody therapy 
induced early tumor regression and, eventually, complete tumor rejection. Furthermore, survival 
was significantly improved, with 50% of animals being tumor-free out to 68 days post treatment. 
 
Discussion. 
PD-L1 is a co-inhibitory checkpoint molecule known for its role in dampening T cell 
responses. However, studies have found that PD-L1 blockade in patients whose tumor cells do 
not express PD-L1 is still effective in inducing tumor regression
102,103
. A recent study also 
showed that treatment of tumor-bearing mice with PD-L1 antibody decreased tumor growth in 
mice deficient in T cells, which points to a myeloid cell-dependent mechanism of action
230
. TAM 
significantly contribute to overall tumor immune-suppression, and TAM express high levels of 
PD-L1 in many tumor types
99,204
. Several reports have suggested additional roles for PD-L1 in 
regulating tumor cell and dendritic cell activity
193,194,196,197,199-203
, but little is known concerning 
its role in regulating macrophage functions.  
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Figure 5.12 Combined therapy with PD-1/PD-L1 antibodies induces early tumor regression 
and tumor-free survival. B16 were implanted into C57Bl/6 mice and mice were treated with 
PD-1 antibody, PD-L1 antibody, or a combination of PD-1 and PD-L1 antibodies. Tumor growth 
was measured every 3 days and the number of tumor-free mice at the end of the study is noted 
for each group (A). Survival curves are shown in (B). Plots represent pooled data from 2 
individual experiments for a total of 15 mice per group. Survival curves were compared by 
Kaplan Meier and log rank (Mantel Cox) test using Prism7 and statistically significant 
differences were denoted P-value **** < 0.0001. 
 
Key findings from our studies were that PD-L1 antibody-treated macrophages exhibited 
significantly greater proliferation, enlargement, and survival, compared to irrelevant antibody  
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treated macrophages. The PD-L1 antibody-treated macrophages were also activated, as revealed 
by upregulation of co-stimulatory molecules and spontaneous pro-inflammatory cytokine 
production. Furthermore, we confirmed changes in macrophage morphology and increased co-
stimulatory markers on human macrophages treated with PD-L1 antibody. These findings are 
particularly remarkable, as M-CSF-cultured macrophages have been shown to have weak ability 
to produce pro-inflammatory cytokines, even with LPS stimulation
231
. Overall, the picture that 
emerges is that of the PD-L1 antibody-treated macrophage as an activated, proliferating 
macrophage with a pro-inflammatory phenotype.  
Other studies confirmed the apparent negative signaling properties of PD-L1 expressed 
by macrophages. For example, treatment with soluble CD80 completely recapitulated the 
phenotype of PD-L1 antibody-treated macrophages. In addition, treatment with soluble PD-1 and 
untreated bone marrow derived macrophages generated from PD-L1
-/-
 mice also exhibited a 
partially activated phenotype. These data suggest that CD80 acts as a ligand for PD-L1 to 
activate macrophages, and that treatment with PD-L1 antibody mimics this interaction. These 
findings expand on the known co-stimulatory role of CD80 in T cell activation to also implicate 
CD80 in stimulating macrophage activation. On the other hand, PD-1 is known to restrain T cell 
activation and these data suggest that it partially activates macrophages. These seemingly 
conflicting roles may be part of a system of maintaining homeostasis, by maintaining some level 
of immune activation to prevent an overly immune-suppressed environment.   
It is unclear why soluble PD-1, or genetic ablation of PD-L1 expression, did not fully 
recapitulate the phenotype of PD-L1 antibody-treated macrophages, but it is possible that the 
strength of the signal delivered by PD-L1 antibody and by soluble CD80 is much stronger than 




compensatory pathways to regulate macrophage activation may have arisen during mouse 
development. These findings also raise the important point that not all PD-L1 antibodies are 
likely to be equivalent with agonistic or antagonistic properties, and that additional in vitro 
screening may be required to identify macrophage-activating clones. In support of this, we found 
that a different anti-murine PD-L1 antibody (clone MlH5) failed to induce the macrophage 
activating effects of the 10F.9G2 clone (data not shown). 
We found that inhibiting the mTOR pathway could partially reverse the macrophage-
activating effects of PD-L1 antibody treatment. Our studies also revealed upregulated mTOR 
pathway activity in macrophages following treatment with PD-L1 antibody. This is particularly 
significant because Akt/mTOR signaling regulates macrophage proliferation, activation, and 
metabolism
232,233
. Thus, PD-L1 may deliver a negative, constitutive signal to downregulate 
macrophage activation in the TME. Therefore, one of the major effects of in vivo treatment with 
PD-L1 antibodies may be to reverse the immune suppressive phenotype of TAM. It is also 
possible that treatment with PD-L1 antibody blocks its interaction with PD-1 on macrophages, 
which has been found to inhibit TAM phagocytosis and anti-tumor immunity
207
.  
Transcriptome profiling showed that PD-L1 antibody treatment changed the macrophages 
to a pro-inflammatory phenotype with increased survival and decreased apoptosis. Genes 
classically associated with pro-inflammatory macrophages were upregulated as well as 
chemoattractant and survival genes. Top downregulated genes included anti-inflammatory genes. 
Furthermore, IPA analysis yielded multiple upregulated inflammatory pathways, one 
downregulated anti-inflammatory pathway, one upregulated survival and proliferation pathway, 
and two downregulated apoptosis pathways. We did not find the mTOR pathway to be 




 found that components of the mTOR pathway were changed at a phosphorylation level 
upon PD-L1 antibody treatment, versus at the level of transcription.   
In the B16 tumor model, tumor-bearing mice treated with PD-L1 antibody exhibited 
increased numbers of TAM and these macrophages upregulated co-stimulatory molecule 
expression. As a result, it is likely that these macrophages were more inflammatory than TAM 
from sham-treated animals. Interestingly, some tumor cells themselves appeared to upregulate 
MHC II expression in animals treated with PD-L1 antibody, possibly mediated by IFN-g released 
by increased numbers of tumor-infiltrating T cells. PyMT tumors established in mice lacking T 
cells (Rag
-/-
) also showed increased inflammatory activation of TAM following PD-L1 antibody 
treatment. Furthermore, these animals had inhibited tumor growth compared to animals treated 
with irrelevant antibody. Recent reports demonstrated that reprogramming macrophages to a pro-
inflammatory phenotype inhibited tumor progression and metastasis
234,235
, which supports our 
findings that PD-L1 antibody-treated TAM had significant anti-tumor effects in vivo. 
The use of PD-1- and PD-L1-blocking antibodies has shown great promise for tumor 
immunotherapy. However, checkpoint molecule blockade alone with a single antibody is not as 
effective as combined treatment, as revealed in patients treated with the combination of PD-1 
and CTLA-4 antibodies
236
. Our findings suggest that the combination of PD-1 and PD-L1 
antibodies, which heretofore would have been considered redundant, may in fact exhibit 
synergistic antitumor activity due to the additional activities of PD-L1 antibodies on macrophage 
function. For example, combined treatment with PD-1 and PD-L1 antibodies in mice with 
established B16 tumors resulted in complete tumor rejection in 50% of animals, compared with 
0% of PD-1 antibody-treated animals and 10% of PD-L1 antibody-treated animals. The potency 
of combined PD-1/PD-L1 antibody therapy is likely due to the targeting of distinct, non-
104	
overlapping cell populations in the tumor. Thus, it is reasonable to propose that combined 
therapy with PD-1 and PD-L1 antibodies be evaluated in clinical trials in suitable cancer 




Final Conclusions and Future Directions 
 
Immunotherapy has become one of the most promising modalities of cancer treatment, 
owing in part to the success of antibodies that bind immune checkpoint molecules. Among these 
checkpoints is the PD-1/PD-L1 signaling axis, which has been targeted to improve anti-tumor T 
cell responses in patients. These efforts have resulted in the FDA approval of several monoclonal 
antibodies for treatment of a variety of different cancers
85-87
. However, it has become apparent 
that only a small subpopulation of patients experience durable responses to immunotherapeutic 
agents, including those targeting PD-1 and PD-L1
95
. Thus, top priorities for the field include 
developing animal models that more readily translate to human medicine, and expanding our 
understanding of immune checkpoints to identify biomarkers that can predict patient response to 
immunotherapy. 
The field of comparative oncology has recognized that spontaneously-occurring cancers 
in dogs is a precious resource for modeling human disease, and that progresses achieved in 
treating human disease can be translated to veterinary medicine. As a result, the success of 
human immunotherapy has prompted the development of canine-specific antibodies that are 
rapidly being tested for the treatment of canine cancers. We, and others, have shown that PD-1 
and PD-L1 antibodies activate canine T cells, and the first use of a canine PD-L1 antibody in 
dogs with cancer showed promising anti-tumor activity
132,133
. However, little is known 
concerning the expression of immune checkpoints and their regulation in canine tumors. We 
therefore completed studies in Chapter 2 that revealed constitutive PD-L1 expression by all 
canine tumor cells lines screened, and inducible PD-L1 expression by primary canine 
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macrophages. We further showed that IFN-γ was primarily responsible for upregulation of PD-
L1 expression by both cell types, though the tumor cells lines were responsive to stimulation by 
specific TLR ligands. These studies suggest that increased expression of PD-L1 is a mechanism 
of tumor-induced immune suppression in canine tumors, and that dogs with cancer may benefit 
from PD-1 and PD-L1 antibody blockade. 
PD-1 antibody therapy is FDA approved for Hodgkin lymphoma and has been shown to 
be highly effective in the treatment of other human lymphomas
160-162
. Therefore, in the studies 
presented in Chapter 3, we conducted an in-depth profiling of PD-1 and PD-L1 expression by 
canine lymphoma. We found increased expression of PD-L1 by BCL compared to healthy B 
cells, and low to negative expression of both PD-1 and PD-L1 by all T cells analyzed. This 
suggests that BCL may be a promising disease for treatment with immunotherapy. However, 
TCL should not be discounted due to the lack of PD-1 or PD-L1 expression by malignant T cells, 
as studies have found PD-L1 antibody blockade to induce tumor regression even in cases where 
the tumor cells did not express PD-L1
102,103
. We believe this activity to be caused in part by the 
inhibition of PD-L1 signaling and concurrent anti-tumor activation of macrophages, as discussed 
in Chapter 5. This is supported by studies of human cancers that found increased PD-L1 




Most canine lymphoma patients develop drug-resistant disease within one year despite 
standard of care chemotherapy. The reasons for this are multifactorial, but emergence of drug-
resistant cancer stem cell (CSC) populations is likely to play a dominant role. In Chapter 3, we 
show upregulated expression of both PD-1 and PD-L1 by canine lymphoma cell lines following 
selection by prolonged, high-dose chemotherapy treatment. Recent studies report a role for PD-
107	
L1 in promoting epithelial-to-mesenchymal transition and tumor metastasis, and PD-L1 
signaling has been found to increase CSC proliferation and resistance to apoptosis in response to 
chemotherapy
193-198
. Thus, studies should be conducted to determine the effect of PD-L1 
signaling in canine lymphoma cells, and the effect of PD-L1 antibodies on CSC phenotype. It is 
plausible that increased PD-L1 expression in response to chemotherapy treatment not only 
shields CSC from immune-killing but also decreases their susceptibility to apoptosis and 
increases their ability to metastasize. If this is the case, dogs with lymphoma could benefit from 
combining chemotherapy to reduce the bulk of disease and PD-L1 antibody therapy to target 
CSC. 





T cells in dogs with BCL that was not present in healthy dog lymph nodes, and similar dual-
positive cells have not been observed in the peripheral blood of dogs with cancer
132
. Future 
studies are warranted to elucidate the functional phenotype and the significance of these cells, as 
well as the factors that regulate their dual expression of PD-1 and PD-L1. PD-1 expression is 
historically known to be induced upon immune cell activation, and PD-L1 is primarily regulated 
by environmental cues. For example, in Chapter 4 we described a novel signaling loop in the 
tumor environment that parallels the regulation of PD-L1 on many cells by IFN-γ, in which a 
pro-inflammatory mediator (TNF-α) secreted by macrophages in response to a tumor cell-
secreted protein (versican) stimulates the upregulation of an immune-suppressive molecule (PD-
L1) in an autocrine fashion. It is likely that activation of tumor-infiltrating T cells in dogs with 
BCL increases their PD-1 expression, and secretion of inflammatory cytokines results in the 
induction of PD-L1 expression by the same cells. Similar to the case of PD-L1 expression by 
108	
canine lymphoma cells, the effect of PD-L1 signaling on tumor-infiltrating T cells should be 
investigated as well as the result of dual signals by PD-1 and PD-L1 in the same cell.    
PD-L1 is primarily known as a ligand that binds PD-1 to deliver a negative signal to T 
cells, and the anti-tumor activity of PD-L1 antibodies has historically been attributed to the 
ability of the antibodies to stimulate an increase in the number and activation of T cells and to a 
decrease in the number and suppressive properties of Tregs
29,48,76-79
. However, the studies we 
described in Chapter 5 demonstrate a previously undescribed negative signaling role for PD-L1 
on macrophages that results in significant anti-tumor activity when altered by PD-L1 antibody 
treatment. We found that PD-L1 constitutively signals in macrophages to induce or maintain an 
immune-suppressive phenotype, and that treatment with PD-L1 antibody or ligation with CD80 
blocks this signaling to reprogram the macrophages to an inflammatory phenotype. These 
findings have important implications due to the increased expression of PD-L1 on TAM that we 
showed in Chapter 4. PD-L1 positivity in tumors, specifically by tumor macrophages, has been 
shown to be predictive of the efficacy of both PD-1 and PD-L1 antibody therapy
99,102,103
. This is 
indicative of the importance of these studies describing the previously unknown role of PD-L1 
signaling in regulating macrophage activation, and also provides rationale for the use of PD-L1 
expression by TAM as a biomarker. Therefore, expression of PD-L1 by tumor macrophages in 
patients should be taken into consideration for understanding how to optimize utilization of 
checkpoint molecule blockade with PD-L1 antibody, either in combination with PD-1 antibody 
or with other T cell expressed co-inhibitory checkpoint molecules. Another factor to be studied is 
the effect of PD-L1 signaling and PD-L1 antibody treatment on tumor cells, since it has been 




may drastically change the desired effect of PD-L1 antibody therapy, since it will likely have off-
target effects on tumor cells rather than simply activating T cells and macrophages.  
Emerging evidence suggests that metabolic shifts are crucial in regulating macrophage 
functions
237
. However, metabolic processes that support changes in macrophage polarization is 
poorly understood
233
. Different macrophage activation states are hypothesized to be supported by 
distinct metabolic programs based on necessary functions. For example, inflammatory 
macrophages upregulate glycolysis to rapidly produce ATP that is needed during acute 
infections, and immune-suppressive macrophages utilize b-oxidation to more efficiently produce 
ATP for defending against slow-growing parasites
238
. It is likely that the phenotypic changes we 
observed in macrophages following PD-L1 antibody treatment are supported by metabolic shifts 
in these cells. The field of immunotherapy would greatly benefit from studies that focus on 
understanding the regulation of macrophages and other immune cells by immune checkpoint 
molecules at a metabolic level. 
In summary, these studies describe the characterization of PD-L1 expression and 
regulation by canine tumors and macrophages as well as the discovery of a novel role for PD-L1 
as a signaling molecule in macrophages. This work provides crucial knowledge for the 
development of checkpoint molecule inhibitors for canine immunotherapy, and further describes 
canine lymphoma as a potential target for PD-1 and PD-L1 blocking antibodies. It also shows a 
previously undescribed means of tumor-mediated immune-suppression via the upregulation of 
PD-L1 on macrophages. This high expression of PD-L1 suppresses not only T cell responses but 
also macrophage anti-tumor activity, and blocking PD-L1 with antibodies activates both cell 
populations. Finally, we demonstrate a novel mechanism for the effectiveness of PD-L1 antibody 
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